



Clinical practice guideline for endoscopic resection of early gastrointestinal cancer

Chan Hyuk Park^{1*}, Dong-Hoon Yang^{2*}, Jong Wook Kim³, Jie-Hyun Kim⁴, Ji Hyun Kim⁵, Yang Won Min⁶, Si Hyung Lee⁷, Jung Ho Bae⁸, Hyunsoo Chung⁹, Kee Don Choi², Jun Chul Park¹⁰, Hyuk Lee⁶, Min-Seob Kwak¹¹, Bun Kim¹², Hyun Jung Lee⁹, Hye Seung Lee¹³, Miyoung Choi¹⁴, Dong-Ah Park¹⁴, Jong Yeul Lee¹⁵, Jeong-Sik Byeon², Chan Guk Park¹⁶, Joo Young Cho¹⁷, Soo Teik Lee¹⁸, Hoon Jai Chun¹⁹

¹Department of Gastroenterology, Hanyang University Guri Hospital, Guri; ²Department of Gastroenterology, Asan Medical Center, Seoul; ³Department of Gastroenterology, Inje University Ilsan Paik Hospital, Goyang; ⁴Department of Gastroenterology, Yonsei University Gangnam Severance Hospital, Seoul; ⁵Department of Gastroenterology, Inje University Busan Paik Hospital, Busan; ⁶Department of Gastroenterology, Samsung Medical Center, Seoul; ⁷Department of Gastroenterology, Yeungnam University Medical Center, Daegu; ⁸Department of Gastroenterology, Seoul National University Hospital Healthcare System Gangnam Center, Seoul; ⁹Department of Gastroenterology, Seoul National University Hospital, Seoul; ¹⁰Department of Gastroenterology, Yonsei University Severance Hospital, Seoul; ¹¹Department of Gastroenterology, Kyung Hee University Hospital at Gangdong, Seoul; ¹²Center for Colorectal Cancer, National Cancer Center, Goyang; ¹³Department of Pathology, Seoul National University Bundang Hospital, Seongnam; ¹⁴National Evidence-based Healthcare Collaborating Agency, Seoul; ¹⁵Center for Gastric Cancer, National Cancer Center, Goyang; ¹⁶Department of Gastroenterology, Chosun University Hospital, Gwangju; ¹⁷Department of Gastroenterology, Cha University Bundang Medical Center, Seongnam; ¹⁸Department of Gastroenterology, Jeonbuk National University Hospital, Jeonju; ¹⁹Department of Gastroenterology, Korea University Anam Hospital, Seoul, Korea

Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by *en bloc* fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly *de novo* methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected. (**Intest Res 2021;19:127-157**)

Key Words: Superficial esophageal squamous cell carcinoma; Early gastric cancer; Early colorectal cancer; Endoscopic resection; Guideline

Received March 28, 2020. Accepted April 11, 2020.

Correspondence to Jong Yeul Lee, Center for Gastric Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea. Tel: +82-31-920-1613, Fax: +82-31-920-2799, E-mail: jylee@ncc.re.kr

Co-Correspondence to Jeong-Sik Byeon, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Tel: +82-2-3010-3905, Fax: +82-2-3010-6157, E-mail: jsbyeon@amc.seoul.kr

*These authors contributed equally to this study.

These guidelines are being co-published in *Intestinal Research*, *Clinical Endoscopy*, *the Korean Journal of Gastroenterology*, *the Korean Journal of Helicobacter and Upper Gastrointestinal Research*, and *Journal of Digestive Cancer Reports* for the facilitated distribution.

INTRODUCTION

Endoscopic resection is a minimally invasive procedure for the treatment of early gastrointestinal cancers including esophageal, gastric, and colorectal cancers.¹ In South Korea, the widespread use of upper gastrointestinal and colorectal endoscopies for screening purposes has increased the rate of early diagnosis of gastrointestinal cancers and, subsequently, the number of endoscopic resections performed for early gastrointestinal cancers.^{2,3} The popularity of endoscopic submucosal dissection (ESD) has rapidly increased with over thousands of ESD procedures performed per year as the procedure allows the *en bloc* resection of a lesion regardless of its size and location.^{3,4} ESD was first introduced in South Korea in 1999 and has been widely accepted as a treatment method for early gastric cancer since 2003. It was performed in 45 tertiary medical institutions in 2014 and is being performed in 44% of the total 287 general hospitals in South Korea.⁵

Endoscopic resection does not require general anesthesia, has fast recovery time relative to the extent of resection, requires a short hospital stay, and is cost-friendly.⁶ However, since the procedure only resects primary local lesions and not the lymph nodes, it is important to screen patients for early gastrointestinal cancer without a possibility of lymph node metastasis before endoscopic resection.^{1,7,8} Additionally, even if endoscopic resection of a local lesion is successful, surgical resection must still be considered to minimize the possibility of cancer recurrence and metastasis when histopathological risk factors associated with cancer recurrence in the lymph nodes are detected in the endoscopic resection specimen. High-resolution endoscopy, image-enhanced endoscopy, chromoscopy, magnification endoscopy, endoscopic ultrasound, and computed tomography (CT) are used in making the clinical decision of whether to perform endoscopic resections,⁹⁻¹⁵ and models have been developed that can predict patients with high likelihoods of lymph node metastasis.^{1,7,8,16,17}

Evidence-based guidelines published from other countries help clinicians with decision-making regarding the examination and treatment of gastrointestinal cancers.¹ However, since the incidence of gastrointestinal cancers and available medical resources vary greatly depending on the target organs (esophagus, stomach, and colon), countries, and regions, direct application of foreign guidelines to the medical situations of South Korea would be inadequate. South Korea still has no clinical practice guidelines for endoscopic resection of early gastrointestinal cancers despite the high need for it, forcing

physicians to refer to foreign clinical practice guidelines or review domestic literatures and apply their results in clinical practice. The present clinical practice guideline comprehensively reviews studies on endoscopic resection of early gastrointestinal cancers conducted in and outside Korea and proposes recommendations for the examination and treatment of early gastrointestinal cancers after considering the epidemiological and clinical characteristics of early gastrointestinal cancers and medical environments in the country. This guideline consists of three sections, each discussing superficial esophageal squamous cell carcinoma (SESCC), early gastric cancer, and early colorectal cancer, and will be subject to revisions and modifications based on future research findings.

METHODS

1. Purpose and Scope of Developing Clinical Practice Guideline

We aimed to develop a treatment guideline for endoscopic resection of early gastrointestinal cancers that caters to the current medical situations in Korea and can be used in clinical settings. The target population for this guideline included male and female adults with SESCO, early gastric cancer, and early colorectal cancer requiring endoscopic resection. The users of this clinical guideline are gastroenterologists who perform gastrointestinal endoscopy in primary, secondary, and tertiary medical institutions. To facilitate the understanding of gastroenterologists, the definitions of terms regarding endoscopic resection were presented in Table 1. The purpose of the guideline is to help these physicians make decisions regarding patient diagnosis, preoperative evaluation, method of resection, and postoperative management. It also aims to guide resident physicians and hospital employees in these aspects and provide patients and healthy persons with realistic and standard medical information.

2. Formation of the Clinical Practice Guideline Committee and Development Process

The Clinical Practice Guideline Committee consisted of the president (Hoon Jai Chun), congress chairman (Soo Teik Lee), and committee members of Korean Society of Gastrointestinal Endoscopy (KSGE) in November 2017. The members of the committee established a development strategy, elected a director of clinical practice guideline project, and reviewed and approved budgets regarding the project. In addition, they reviewed proposed recommendations and ensured editorial

Table 1. Definition of Terms Related to Endoscopic Resection

Term	Definition
<i>En bloc</i> resection	Resection of a tumor in one piece without visible residual tumor
Complete resection	Resection of a tumor without histological evidence of tumor cell involvement on the lateral and vertical resection margins
Curative resection	Resection of an early gastrointestinal cancer, which is considered curative based on complete resection and minimal to no risk of lymph node metastasis The criteria for curative resection are different according to the type of cancers (early esophageal, gastric and colorectal cancers)

independence and participation of all involved parties in the guideline editing process. The Clinical Practice Guideline Committee in January, 2020 (Joo Young Cho, the president and Chan Guk Park, the congress chairman) reviewed the final version of guideline and approved its publication.

The Clinical Practice Guideline Committee formed the KSGE Task Force on Clinical Practice Guideline, which directed the development of the clinical practice guideline for endoscopic resection of early gastrointestinal cancers. For multidisciplinary development of the clinical practice guideline, Jeong-Sik Byeon, a gastroenterologist and member of KSGE, was appointed as the director of the KSGE Task Force on Clinical Practice Guideline along with the recommended medical experts of KSGE (Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, Chan Hyuk Park, Si Hyung Lee, and Jong Yeul Lee), the Korean Society of Gastroenterology (Jung Ho Bae, Dong-Hoon Yang, Hyunsoo Chung, and Kee Don Choi), the Korean College of *Helicobacter* and Upper Gastrointestinal Research (Jun Chul Park and Hyuk Lee), the Korean Association for the Study of Intestinal Diseases (Min-Seob Kwak), the Korean Society of Gastrointestinal Cancer (Bun Kim and Hyun Jung Lee), and the Korean Society of Pathologists (Hye Seung Lee) as members of the KSGE Task Force. Additionally, two experts (Dong-Ah Park and Miyoung Choi) of clinical practice guideline development from the National Evidence-based Healthcare Collaborating Agency participated in the guideline development. Three sub-committees were formed for each gastrointestinal cancer—SESCC (team leader: Kee Don Choi), early gastric cancer (team leader: Jong Yeul Lee), and early colorectal cancer (Dong-Hoon Yang)—to ensure systematic guideline development. The sub-committees selected key questions for the guideline, conducted a literature search, derived recommendations, and wrote and edited the first draft of the guideline.

To maintain consistency in guideline development among the sub-committees, the KSGE Task Force on Clinical Practice Guideline held four meetings since December 22, 2017. The Task Force also held two workshops to establish a methodolo-

gy for guideline development and review the development process (March 12, 2018 and November 10, 2018). These workshops were accompanied by an education session on the methods of guideline development, grading of scientific evidence and recommendations, and achievement of recommendation consensus. The Task Force chose the *de novo* guideline development approach. The sub-committees for guideline development developed the clinical practice guideline through online and in-person meetings.

3. Selection of Key Questions

Selection criteria were established, and a questionnaire was formed through the PICO process wherein key questions to be included in the clinical practice guideline were derived. P (population) represents patients with SESCO, early gastric cancer, and early colorectal cancer; I (intervention) represents interventions including diagnostic and treatment methods; C (comparison) includes patient groups for comparison between specific intervention methods; and O (outcome) represents the usefulness of diagnosis or treatment outcome. The PICO processes are presented in Supplementary Material 1. The members of the sub-committees for guideline development gathered questionnaires containing key questions and rated the importance of each question to determine the questions to be included in the clinical practice guideline. Studies were excluded if any of the following was noted: (1) the studies did not involve human subjects or the target patients of the guideline's key questions; (2) the studies did not conduct an intervention related to the key questions and an intervention for comparison; (3) the studies were review articles, case reports or abstracts only; (4) the studies were not published in English or Korean; and (5) the studies' original copies could not be found. In case where ≥ 2 studies used the same groups of subjects, the smaller studies were excluded.

4. Literature Search and Selection

A literature search was conducted using the MEDLINE, EM-

BASE, Cochrane Library, KoreaMed, and the Guideline International Network in August 2018 by Miyoung Choi, a researcher from the National Evidence-based Healthcare Collaborating Agency. Keywords related to esophageal cancer (“esophageal” OR “esophagus” OR “oesophageal” OR “oesophagus” OR “gullet”) AND (“cancer\$” OR “tumo?r” OR “carcinoma\$” OR “adenocarcinoma\$” OR “neoplas\$”), gastric cancer (“stomach” OR “gastric”) AND (“cancer\$” OR “tumo?r” OR “carcinoma\$” OR “adenocarcinoma\$” OR “neoplas\$”), colorectal cancer (“colon\$” OR “rectum” OR “colorectal” OR “rectal”) AND (“polyp\$” OR “cancer” OR “adenoma\$” OR “adenocarcino\$” OR “carcino\$” OR “tumo?r”), and endoscopic resection (“endoscop\$”) AND (“dissection” OR “resection” OR “treat\$” OR “ESD”) were used. Different keywords or different combinations of keywords were also used based on the key questions. Duplicate articles were removed. Two committee members were assigned to the key questions, and they independently selected articles according to the inclusion and exclusion criteria. They first removed articles irrelevant to the guideline development based on titles and abstracts and then reviewed the entire content of the remaining articles for further screening. Any disagreements between the two members were resolved through negotiations. In case they did not reach a consensus, the team leader of the corresponding sub-committee made the final decision. The flowchart showing the searching process is shown in Supplementary Material 2.

5. Bias Assessment and Summary of Evidence and Recommendation Grade

The validity of the selected articles that would form the basis of the clinical practice guideline was assessed using systematic methods. The revised Cochrane Risk of Bias Tool was used to evaluate randomized comparative studies,^{18,19} and RoBANS 2.0 and Newcastle–Ottawa assessment scale were used to evaluate nonrandomized studies.²⁰ The QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) tool was used for diagnostic studies.²¹ The GRADE (Grading of Recommendations Assessment, Development and Evaluation) method was used to present summaries of evidence.²² Although, by default, randomized comparative studies have high levels of evidence, and observational studies low levels of evidence, a study’s final level of evidence was determined as high, moderate, low, or very low based on various factors affecting the quality of research.

The grade of recommendation was determined as strong or weak based on the balance between positive and negative effects of the recommendation, quality of evidence, values, and preferences. Strong recommendations are recommended to most patients since the recommendations have more positive than negative effects, are supported by high-quality evidence, are highly valuable, and are more strongly preferred than other interventions. Weak recommendations are also beneficial for many patients although they have relatively small positive effects that are supported by weak evidence. Alternative inter-

Table 2. Summary and Strength of Recommendations for SESCC

Statement E1:	We recommend endoscopic resection for SESCC without distant or lymph node metastasis, excluding those with obvious submucosal invasion (Grade of recommendation: strong, Level of evidence: moderate).
Statement E2:	We recommend Lugol chromoendoscopy and/or image-enhanced endoscopy to define the extent of lesion before endoscopic treatment of SESCC (Grade of recommendation: strong, Level of evidence: moderate).
Statement E3:	We recommend endoscopic ultrasound to define the stage of SESCC before endoscopic treatment (Grade of recommendation: strong, Level of evidence: moderate).
Statement E4:	We suggest magnifying endoscopy with narrow band imaging for SESCC to assess the depth of invasion before endoscopic treatment (Grade of recommendation: weak, Level of evidence: low).
Statement E5:	We recommend endoscopic submucosal dissection rather than endoscopic mucosal resection for <i>en bloc</i> and curative resection of SESCC confined to the mucosa (Grade of recommendation: strong, Level of evidence: moderate).
Statement E6:	We recommend oral steroid or local steroid injection therapy for patients who develop mucosal defects in >75% of the esophageal circumference after endoscopic submucosal dissection to prevent esophageal stricture (Grade of recommendation: strong, Level of evidence: moderate).
Statement E7:	No additional treatment is recommended after <i>en bloc</i> complete resection of SESCC invading no more than the lamina propria with no lymphovascular invasion because of a very low risk of lymph node metastasis (Grade of recommendation: strong, Level of evidence: moderate). As the risk of lymph node metastasis of a tumor invading into the muscularis mucosa without lymphovascular invasion is low, a close follow-up after <i>en bloc</i> complete endoscopic resection can be considered without additional treatment (Grade of recommendation: weak, Level of evidence: low). In case of a tumor with submucosal invasion, lymphovascular invasion, and/or positive vertical resection margin, additional treatment is recommended (Grade of recommendation: strong, Level of evidence: moderate).

SESCC, superficial esophageal squamous cell carcinoma.

vention method may be chosen instead of the weakly recommended intervention depending on the health professionals' values and preferences. Tables 2-4 summarize the recommendations with their grades of recommendation and levels of evidence, respectively.

6. Review and Approval

An editorial committee consisting of 29 members of KSGE Steering Committee, 14 members from the Insurance Committee, and 15 members from the Research Group for Endoscopic Submucosal Dissection was formed in August, 2019. The members evaluated the first draft of the guideline using open-ended questions. The draft was revised by the KSGE Task Force on Clinical Practice Guideline and re-evaluated by the editorial committee to ensure information balance and

guideline completion. For an external review of the guideline, a public meeting in which 38 gastrointestinal endoscopy experts participated was held on August 18, 2019 during the 61st seminar of KSGE in which doctors and nurses from all over the country gathered. Opinions about the guideline were shared during the public meeting and the final draft of guideline was made after its revision based on discussion during the public meeting.

7. Provision of Clinical Practice Guideline and Plans for Future Updates

For wide provision and distribution of the clinical practice guideline, we plan to publish the guideline in *Intestinal Research*, *Clinical Endoscopy*, *the Korean Journal of Gastroenterology*, *the Korean Journal of Helicobacter and Upper Gastroin-*

Table 3. Summary and Strength of Recommendations for Early Gastric Cancer

Statement G1:	We recommend chromoendoscopy/image-enhanced endoscopy to determine the extent of lesion before endoscopic treatment of early gastric cancer (Grade of recommendation: strong, Level of evidence: moderate).
Statement G2:	Endoscopic ultrasonography before endoscopic resection of early gastric cancer may be helpful in determining the depth of invasion in some patients with early gastric cancer (Grade of recommendation: weak, Level of evidence: moderate).
Statement G3:	We recommend endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma meeting endoscopically estimated tumor size ≤ 2 cm and endoscopically suspected mucosal cancer without ulcer (Grade of recommendation: strong, Level of evidence: moderate).
Statement G4:	We suggest endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma meeting the following endoscopic findings: 1) mucosal cancer > 2 cm without ulcer, or 2) mucosal cancer ≤ 3 cm with ulcer (Grade of recommendation: weak, Level of evidence: moderate).
Statement G5:	We suggest endoscopic resection for poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, and signet ring cell carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤ 2 cm, endoscopically mucosal cancer, and no ulcer in the tumor (Grade of recommendation: weak, Level of evidence: low).
Statement G6:	We recommend prophylactic hemostasis of visible vessels on the post-resection ulcer caused by endoscopic resection of early gastric cancer to lower the risk of delayed bleeding (Grade of recommendation: strong, Level of evidence: low).
Statement G7:	We recommend proton pump inhibitors to decrease the risk of symptoms and complications associated with iatrogenic ulcers caused by endoscopic resection of early gastric cancer (Grade of recommendation: strong, Level of evidence: high).
Statement G8:	We recommend endoscopic closure as the first treatment option for perforation that occurred during endoscopic resection of early gastric cancer (Grade of recommendation: strong, Level of evidence: low).
Statement G9:	We recommend surgical gastrectomy if histopathological evaluation after endoscopic resection of early gastric cancer meets the criteria for non-curative resection. An exception applies if cancer invasion is observed at the horizontal resection margin only (Grade of recommendation: strong, Level of evidence: moderate).
Statement G10:	We recommend additional endoscopic management rather than surgical gastrectomy if histopathological evaluation of endoscopically resected early gastric cancer specimen shows positive involvement at the horizontal resection margin without any other findings compatible with non-curative resection (Grade of recommendation: strong, Level of evidence: moderate).
Statement G11:	We recommend <i>Helicobacter pylori</i> eradication treatment after endoscopic resection of early gastric cancer in <i>H. pylori</i> -infected patients (Grade of recommendation: strong, Level of evidence: high).
Statement G12:	We recommend regular surveillance endoscopy every 6–12 months for patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria for early detection of metachronous gastric cancer (Grade of recommendation: strong, Level of evidence: low).
Statement G13:	We suggest regular abdominopelvic computed tomography scan of 6- and 12-month interval for detection of extra-gastric recurrence after curative endoscopic resection of early gastric cancer based on absolute and expanded criteria (Grade of recommendation: weak, Level of evidence: low).

Table 4. Summary and Strength of Recommendations for Early Colorectal Cancer

Statement C1: Poor histologic types (poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma), deep submucosal invasion, lymphovascular invasion, and intermediate-to-high-grade tumor budding at the site of deepest invasion are risk factors of lymph node metastasis in early colorectal cancer (Grade of recommendation: strong, Level of evidence: moderate).
Statement C2: Endoscopic resection of submucosal colorectal cancer with a high risk of lymph node metastasis has a higher recurrence rate than surgical resection. Therefore, we recommend additional surgery if histological signs after endoscopic resection suggest a high risk of lymph node metastasis (Grade of recommendation: strong, Level of evidence: high).
Statement C3: We recommend endoscopic assessment of pit patterns and vascular patterns to estimate the depth of submucosal invasion before endoscopic resection of early colorectal cancer (Grade of recommendation: strong, Level of evidence: high).
Statement C4: <i>En bloc</i> and histologically complete resection should be achieved for endoscopic treatment of a suspected or established early colorectal cancer. We recommend endoscopic submucosal dissection for the treatment of endoscopically resectable early colorectal cancer which cannot be resected <i>en bloc</i> using endoscopic mucosal resection technique (Grade of recommendation: strong, Level of evidence: moderate).

testinal Research, and *Journal of Digestive Cancer Reports*. We will also upload the guideline on the website of KSGE and submit it to the Korean Medical Guideline Information Center. Because we expect slow distribution of guidelines among endoscopists through databases for clinical practice guidelines, KSGE, the main institution for developing the guideline, will send out the guideline for free via various routes including emails and will actively advertise the guideline in academic conferences, seminars, and workshops. Current recommendations in the clinical practice guideline are based on research conducted up to date and will be subject to revisions based on future findings.

8. Limitations

The most critical limitation of this clinical practice guideline is the insufficiency of data pertaining to Koreans. Data from foreign countries cannot be directly used to develop a guideline for the Korean population since the epidemiological and clinical characteristics of early gastrointestinal cancers differ between Korean and foreign populations. In addition, this clinical practice guideline does not aim to provide an absolute treatment standard that physicians should use to manage patients in real clinical settings but aims to help physicians make evidence-based clinical judgments with regard to the treatment of early gastrointestinal cancers. A physician must examine various clinical aspects of a patient before making any treatment decisions. This clinical practice guideline shall not be used to restrict medical practice of physicians, as health insurance criteria, or to make legal judgments regarding treatments performed on a particular patient.

9. Editorial Independence

This clinical practice guideline is a project selected and funded by KSGE. KSGE did not influence the process of guideline development in any manner. All parties involved in the guide-

line development had no conflict of interests regarding the guideline development.

SUPERFICIAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Statement E1

We recommend endoscopic resection for SESCC without distant or lymph node metastasis, excluding those with obvious submucosal invasion (Grade of recommendation: strong, Level of evidence: moderate).

SESCC is squamous cell carcinoma of the esophagus that is localized to the mucosa or submucosa. SESCC without distant metastasis and with a low risk of lymph node metastasis is a good target of endoscopic resection. Although endoscopic resection of SESCC can conserve the esophagus, it is important to carefully select patients who will receive the procedure since there is still a possibility of lymph node metastasis. The National Comprehensive Cancer Network guidelines recommend endoscopic resection for SESCC localized to the mucosa and esophagectomy in the presence of submucosal invasion.²³ The Japan Esophageal Society defines mucosal cancer invading only as deep as the lamina propria as an absolute indication for endoscopic resection as the cancer rarely metastasizes to the lymph nodes.¹⁷ The European Society of Gastrointestinal Endoscopy (ESGE) defines esophageal cancer invading the lamina propria without lymph node metastasis as an absolute indication for endoscopic resection.¹ Thus, the depth of invasion of SESCC must be accurately determined using endoscopy, endoscopic ultrasound, and magnifying endoscopy with narrow band imaging (NBI) before performing endoscopic resection of SESCC.²⁴⁻²⁸ However, the evaluation of invasion depth is not perfectly accurate. Therefore, it is ad-

visible to perform endoscopic resection instead of esophagectomy to avoid unnecessary operations when there is no obvious submucosal invasion because esophagectomy has high morbidities and mortalities.²⁹⁻³¹ Recent Korean studies report no significant difference in long-term survival between patients with SESCC without obvious submucosal invasion who underwent endoscopic resection as their first treatment and those who underwent esophagectomy, and the rate of postoperative complications was significantly higher in the operated patients.³² This may be because additional operations lowered the risk of recurrence following non-curative endoscopic resection. A Chinese study also reported no significant difference in survival rates between patients with SESCC who underwent endoscopic resection and those who underwent surgical resection and reported a lower incidence of treatment-related complications in the former group.³³ These results show that performing endoscopic resection prior to a surgical resection of SESCC without obvious submucosal invasion may be an effective treatment strategy.

Statement E2

We recommend Lugol chromoendoscopy and/or image-enhanced endoscopy to define the extent of lesion before endoscopic treatment of SESCC (Grade of recommendation: strong, Level of evidence: moderate).

SESCC manifests as erythematous lesions, subtle discoloration, or nodules. In addition, synchronous SESCC lesions of various sizes are not rare, which are difficult to be distinguished from noncancerous lesions only by white light endoscopy. Therefore, accurate measurement of the size and horizontal border of these lesions is challenging. Lugol chromoendoscopy, which applies the fact that the keratin layer of the mucosa is destroyed by the cancer, is the most effective chromoendoscopy to identify the SESCC lesions. The normal esophageal mucosa turns dark brown when sprayed with Lugol's solution, whereas the mucosa affected by SESCC exhibits a "pink-color sign." That is, the mucosa remains light brown and turns pink 2–3 minutes after being sprayed with the solution.³⁴ Studies evaluating the efficacy of Lugol chromoendoscopy in diagnosing lesions suggestive of SESCC in white light endoscopy reported Lugol chromoendoscopy to be 73.8%–93.4% accurate in differentiating high-grade adenoma and SESCC from low-grade adenoma and noncancerous lesions.^{34,35} Thus, Lugol chromoendoscopy effectively assesses the horizontal border of SESCC before endoscopic resection.

Image-enhanced endoscopy is a quick process that causes no inflammation around SESCC lesions unlike Lugol chromoendoscopy. Image-enhanced endoscopy with NBI is the most widely studied image-enhanced endoscopy technique.³⁶ In a study of 90 patients with high-grade adenoma and SESCC, the accuracy of image-enhanced endoscopy with NBI was significantly higher than that of white light endoscopy (92% vs. 67.8%), and was similar to that of Lugol chromoendoscopy (92% vs. 93.4%).³⁷ In a prospective study that compared the diagnostic accuracy of detecting SESCC between Lugol chromoendoscopy and image-enhanced endoscopy with NBI in 303 patients with high risk of SESCC, the accuracy of the image-enhanced endoscopy with NBI was 91.2%, which was not inferior to that of Lugol chromoendoscopy.³⁸ Based on these results, we recommend Lugol chromoendoscopy or image-enhanced endoscopy to determine the border of SESCC prior to endoscopic resection.

Statement E3

We recommend endoscopic ultrasound to define the stage of SESCC before endoscopic treatment (Grade of recommendation: strong, Level of evidence: moderate).

Endoscopic treatments of SESCC have better prognoses when the depth of invasion is shallow, and unlike gastric cancer, SESCC invading the muscularis mucosa poses a risk of lymph node metastasis.³⁹ Accurate staging of SESCC before an endoscopic treatment is thus important. For SESCC, endoscopic ultrasound accurately determines the level of infiltration by the primary tumor (T stage) and the presence or absence of lymph node metastasis (N stage). A study reported endoscopic ultrasound to be 81.6% sensitive and 99.4% specific in staging esophageal cancer invading the mucosa and submucosa.⁴⁰ A meta-analysis of 19 studies reported endoscopic ultrasound as an excellent technique to differentiate mucosal invasion from submucosal invasion in SESCC (area under the summary receiver operating characteristic [ROC] curve = 0.93).²⁶ Additionally, in another meta-analysis that investigated whether endoscopic ultrasounds can differentiate between esophageal cancer invasions in the lamina propria, muscularis mucosa, and submucosa, endoscopic ultrasounds showed an excellent diagnostic performance (area under the summary ROC curve = 0.98).¹¹

Statement E4

We suggest magnifying endoscopy with NBI for SESCC to assess the depth of invasion before endoscopic treatment (Grade of recommendation: weak, Level of evidence: low).

A large-scale, multi-institutional prospective study that investigated whether magnifying endoscopy with NBI can accurately assess the depth of invasion of esophageal cancer reported magnifying endoscopy with NBI to be not superior to conventional endoscopy for squamous cell carcinoma (accuracy of magnifying endoscopy with NBI, 65.3%; accuracy of conventional endoscopy, 71.4%; $P=0.375$).¹⁰ A prospective study conducted in Japan also reported that magnifying endoscopy with NBI is no better than high-resolution endoscopy and high-frequency endoscopic ultrasound.⁴¹ However, a recent large-scale retrospective study that investigated the performance of magnifying endoscopy with NBI in the assessment of the depth of SESCC reported a positive predictive value of 93% for epithelial/lamina propria invasion, 65% for muscularis mucosal/superficial submucosal invasion, and 77% for deep submucosal invasion, demonstrating that magnifying endoscopy with NBI is useful for determining the depth of invasion of SESCC before an endoscopic treatment.⁴² Therefore, given that the operator is highly experienced, it may be useful to perform magnifying endoscopy with NBI to determine the depth of invasion of SESCC before endoscopic resection.

Statement E5

We recommend ESD rather than EMR for *en bloc* and curative resection of SESCC confined to the mucosa (Grade of recommendation: strong, Level of evidence: moderate).

Endoscopic mucosal resection (EMR) is popular as it is relatively easy to perform and is associated with low risks of complications. However, studies have reported high local recurrence rates of 2.8%–9.8% after EMR because *en bloc* resection is difficult by EMR, especially for large lesions.^{43–47} ESD is a technically demanding procedure with high risks of complications but is nonetheless considered appropriate for treating SESCC due to the high *en bloc* and curative resection rates and low risks of local recurrence. Resection techniques are usually chosen based on lesion size and auxiliary factors such as the patient's conditions and the operator's level of experience.

There is no randomized study comparing EMR and ESD for SESCC. In a meta-analysis of retrospective studies, ESD had higher *en bloc* and curative resection rates than EMR regard-

less of the lesion size. ESD had a significantly lower rate of postoperative local recurrence than EMR (0.3% vs. 11.5%; odds ratio [OR], 0.08; 95% confidence interval [CI], 0.03–0.23; $P<0.001$). The rate of postoperative perforation was higher for ESD than for EMR (4.0% vs. 1.3%; OR, 2.19; 95% CI, 1.08–4.47; $P=0.03$). However, no significant difference was noted in the rate of stricture formation or bleeding between the two procedures.⁴⁸ Although studies report no difference in the rate of *en bloc* and curative resection rates between cap-assisted EMR and ESD for lesions measuring < 10 to 15 mm,^{43,46,47} one meta-analysis reported a higher *en bloc* resection rate for ESD for lesions measuring < 10 mm (OR, 3.58; 95% CI, 1.84–7.02; $P<0.001$).⁴⁹

We recommend to consider ESD first regardless of the lesion size since ESD has higher *en bloc* and curative resection rates than EMR for SESCC confined to the mucosa and has complication risks within an acceptable range. In case the operator lacks experience with ESD, performing EMR could be considered for only small lesions < 10 mm in size.

Statement E6

We recommend oral steroid or local steroid injection therapy for patients who develop mucosal defects in >75% of the esophageal circumference after ESD to prevent esophageal stricture (Grade of recommendation: strong, Level of evidence: moderate).

ESD can lead to scar formation around the surgical site followed by esophageal strictures. Ono et al.⁵⁰ reported that the risk of esophageal stricture increased in the presence of mucosal defects in >75% of the esophageal circumference. Furthermore, 66%–88% of patients with mucosal defects in >75% of the esophageal circumference that were left untreated after esophageal ESD developed an esophageal stricture.^{51–56} Patients who developed mucosal defects in 100% of the esophageal circumference required an average of 33.5 endoscopic balloon dilation (EBD) procedures to treat esophageal stricture.⁵⁷

To prevent stricture after esophageal ESD, oral steroid administration or local steroid injection therapy is used. For oral steroid therapy, prednisolone is administered at 30 mg per day starting 1 or 2 days after the procedure, and the dose is decremented over 2–12 weeks.^{54,55,57} In six studies comparing patients who received oral steroids following ESD to those who did not, oral steroid administration significantly reduced the rate of esophageal stricture formation by 73% (69%–80% without oral steroids and 18%–23% with oral steroids) (OR,

0.27; 95% CI, 0.13–0.58).^{54,55} Local steroid injection therapy also effectively prevents esophageal stricture. Studies reported a 78% reduction in the rate of esophageal stricture formation following local injections of triamcinolone or dexamethasone at the site of ESD (OR, 0.32; 95% CI, 0.13–0.83).^{51-53,58}

In a study that compared oral steroid therapy and preventive EBD, 32% of patients who underwent EBD twice per week for 8 weeks had an esophageal stricture, whereas only 5% of patients who were orally administered prednisolone at 30 mg per day starting 2 days after ESD and had the dose gradually decreased over 8 weeks had an esophageal stricture, demonstrating that oral steroid administration is superior to preventive EBD for the prevention of esophageal stricture.⁵⁶

Studies on steroid administration for the prevention of esophageal stricture mostly involve patients who develop mucosal defects in >75% of the esophageal circumference and are at high risk of esophageal stricture. In a study that investigated the effect of local steroid injections in patients who underwent esophageal ESD regardless of the size of mucosal defect, local steroid injections had a 70% preventive effect on esophageal strictures with the rate of stricture formation being 11% in patients who received local steroid injections and 36% in those who did not receive them (OR, 0.30; 95% CI, 0.13–0.83).⁵⁸ However, considering the risk of esophageal perforation and adverse reactions associated with local steroid injections, it is advisable to consider oral steroid or local steroid injection therapy only for patients who develop mucosal defects in >75% of the esophageal circumference who are at high risk of esophageal stricture.

Statement E7

No additional treatment is recommended after *en bloc* complete resection of SESCC invading no more than the lamina propria with no lymphovascular invasion because of a very low risk of lymph node metastasis (Grade of recommendation: strong, Level of evidence: moderate). As the risk of lymph node metastasis of a tumor invading into the muscularis mucosa without lymphovascular invasion is low, a close follow-up after *en bloc* complete endoscopic resection can be considered without additional treatment (Grade of recommendation: weak, Level of evidence: low). In case of a tumor with submucosal invasion, lymphovascular invasion, and/or positive vertical resection margin, additional treatment is recommended (Grade of recommendation: strong, Level of evidence: moderate).

Since the risk of lymph node metastasis associated with SES-

CC is closely related to a tumor's depth of invasion, it is important to accurately evaluate the depth of invasion for deciding whether the endoscopic resection is curative or non-curative.⁵⁹⁻⁶¹ Histopathological analyses of patients who underwent esophagectomy with dissection of the regional lymph nodes show that the risk of lymph node metastasis is 26.0%–53.8% in the presence of submucosal invasion of esophageal cancer.⁵⁹⁻⁶⁸ Moreover, 8.3%–53.1% of the patients had lymph node metastasis even when esophageal cancer invaded only the upper third of the submucosa. The Japan Esophageal Society and the ESGE guidelines define SESCC with a shallow submucosal invasion of ≤ 200 μm as a relative indication for endoscopic resection. However, data regarding the frequency of lymph node metastasis by SESCC with shallow submucosal invasion of ≤ 200 μm is limited.⁶⁷ The rate of lymph node metastasis is lower but not negligible at 0.0%–15.4% for esophageal cancer confined to the mucosa.⁵⁹⁻⁶⁷ Among esophageal cancers confined to the mucosa, invasion of muscularis mucosa is at a higher risk of lymph node metastasis than invasion of lamina propria (8.0%–27.0% vs. 0.0%–8.7%). The risk of lymph node metastasis is associated with vascular or lymphatic invasion.^{59,65,67,69,70} A large-scale Japanese study reported a 5-year cumulative incidence of metastasis of primary esophageal cancer invading the muscularis mucosa following endoscopic resection of only 0.7%, suggesting that SESCC invading the muscularis mucosa can still be an indication for endoscopic resection if no lymphovascular invasion is observed.⁶⁸ Two observational studies at Korean institutions supports the claim that endoscopic resection can be a safe and curative treatment option in SESCC invading to the mucosa. In those studies, no death due to esophageal cancer occurred during a long-term follow-up of patients who underwent endoscopic resection of SESCC with invasion up to the mucosa.^{71,72} There are conflicting research results regarding the association between undifferentiated esophageal cancer and the risk of lymph node metastasis, indicating that undifferentiated esophageal cancer cannot be yet used as an absolute contraindication of endoscopic resection for SESCC. Additional data analyses are needed to derive more confirmative conclusions.^{59,61,65,68}

Endoscopic resection is considered curative if histopathological evaluation shows that SESCC does not invade beyond the lamina propria and does not invade the vascular or lymphatic channels. In this case, a close follow-up may be conducted without additional operations. Following *en bloc* resection of SESCC with muscularis mucosal invasion and no lymphovascular invasion, a follow-up can be considered without

additional operations after considering the patient's age, accompanying diseases, conditions, and risk of operation since the risk of lymph node metastasis is low. In case of unsuccessful *en bloc* resection, follow-up strategies considering the possibility that the histopathological assessment may have been inaccurate are necessary.

Additional treatments are needed in case of non-curative resection such as positive vertical resection margin and submucosal invasion and/or lymphovascular invasion suggesting the possibility of lymph node metastases. Esophagectomy with dissection of the regional lymph nodes is the standard treatment for non-curative endoscopic resection. However, since esophagectomy has high postoperative morbidities of 30%–40% and mortalities of 1%–2%, physicians must consider the patient's conditions before deciding whether to perform the surgery or not.²⁹⁻³¹ Studies have reported relatively satisfactory outcomes of chemoradiation therapy for non-curative endoscopic resection of SESCC, suggesting that chemoradiation therapy might become a new treatment strategy for non-curative endoscopic resection.⁷³⁻⁷⁸

EARLY GASTRIC CANCER

Statement G1

We recommend chromoendoscopy/image-enhanced endoscopy to determine the extent of lesion before endoscopic treatment of early gastric cancer (Grade of recommendation: strong, Level of evidence: moderate).

Clearly identifying the horizontal border of the lesion before endoscopic resection reduces local recurrence and increases the likelihood of a complete resection. Chromoendoscopy has been used widely to accurately measure lesion borders. Recent advances in endoscopy technology led to the advent of NBI and magnifying endoscopy now commonly used in clinical settings.^{12,79} A study reported that chromoendoscopy using indigo carmine more accurately estimated lesion borders in early gastric cancer than white light endoscopy (75.9% vs. 50.0%), and chromoendoscopy using indigo carmine and acetic acid estimated lesion borders with 90.7% accuracy.⁸⁰ A Korean study also reported that chromoendoscopy using indigo carmine and acetic acid estimated lesion borders in early gastric cancer more accurately than white light endoscopy (84.1% vs. 66.9%).⁸¹ In a study that compared the accuracy of border prediction between magnifying endoscopy with NBI and chromoendoscopy using indigo carmine, the former tech-

nique estimated horizontal borders of lesions more accurately than the latter (81.1% vs. 72.6%).¹² Magnifying endoscopy with NBI was also superior to white light endoscopy in terms of sensitivity and specificity for assessment of lesion borders (sensitivity, 92.9% vs. 42.9%; specificity, 94.7% vs. 61.0%).¹³ Based on these results, we recommend chromoendoscopy and image-enhanced endoscopy to determine the extent of resection before endoscopic resection of early gastric cancer.

Statement G2

Endoscopic ultrasonography before endoscopic resection of early gastric cancer may be helpful in determining the depth of invasion in some patients with early gastric cancer (Grade of recommendation: weak, Level of evidence: moderate).

Endoscopic ultrasonography is useful for assessing the depth of invasion in gastric cancer and determining the presence or absence of lymph node metastasis. In a meta-analysis on 54 studies evaluating the efficacy of endoscopic ultrasonography in predicting the depth of invasion of a primary tumor in 5,601 patients with gastric cancer, endoscopic ultrasonography accurately differentiated between T3-T4 lesions and T1-T2 lesions with 86% sensitivity and 91% specificity.¹⁴ However endoscopic ultrasonography before endoscopic resection of early gastric cancer has limited accuracy in predicting the depth of invasion.⁸²⁻⁸⁸ In a large-scale Korean prospective study, the accuracy of distinguishing mucosal and submucosal invasion in early gastric cancer was 67.4% with endoscopic ultrasonography, which was not superior to 73.7% of conventional endoscopy.⁸⁴ Another Korean study also reported no significant difference in the accuracy of depth of invasion prediction in early gastric cancer between endoscopic ultrasonography using a miniprobe and white light endoscopy (81.4% vs. 78.9%).⁸³ However, some studies report that endoscopic ultrasonography may be useful for investigating the depth of invasion of early gastric cancer. According to a Japanese study, the diagnostic accuracy of endoscopic ultrasound was higher than that of white light endoscopy in predicting the depth of invasion of early gastric cancer (71% vs. 63%).⁸⁵ A recent study reported that endoscopic ultrasonography had higher accuracy than chromoendoscopy in predicting the depth of invasion of early gastric cancer (79.1% vs. 76.5%) and that the depth of invasion could be predicted with 88.3% accuracy using both chromoendoscopy and endoscopic ultrasonography.⁸² Based on these studies, there is still a role for endoscopic ultrasonog-

raphy to help differentiating mucosal or submucosal infiltration of early gastric cancer. Therefore, for patients who show signs of submucosal invasion in a white light endoscopic examination, endoscopic ultrasonography could be used to more accurately examine the depth of invasion of a tumor before endoscopic resection.⁸⁹

Statement G3

We recommend endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma meeting endoscopically estimated tumor size ≤ 2 cm and endoscopically suspected mucosal cancer without ulcer (Grade of recommendation: strong, Level of evidence: moderate).

Endoscopic resection is a local treatment for early gastric cancer with a negligible risk of lymph node metastasis. Before Gotoda et al.⁹⁰ proposed expanded indications for endoscopic resection in 2000, well or moderately differentiated tubular or papillary gastric adenocarcinoma measuring ≤ 2 cm in diameter confined to the mucosa without ulcer and submucosal invasion was an indication for endoscopic resection. Thus, for these lesions, endoscopic resection must be considered as the first line of treatment. The risk of lymph node metastasis must be considered before performing endoscopic resection of early gastric cancer. Several studies have reported the risk of lymph node metastasis to be negligibly low in lesions that satisfy the aforementioned indications (0.0%–0.3%).⁹⁰⁻⁹² In addition, Korean studies reported no significant difference in the 5-year survival rate between endoscopic resection and surgical resection (93.6%–96.4% vs. 94.2%–97.2%),⁹³⁻⁹⁵ They also reported no significant difference in the 10-year survival rate between endoscopic resection and surgical resection (81.9% vs. 84.9%).⁹³ However, endoscopic resection had a higher 5-year cumulative incidence of metachronous gastric cancer than surgical resection (5.8%–10.9% vs. 0.9%–1.1%).⁹³⁻⁹⁵ Endoscopic resection preserves the entire stomach, which can lead to metachronous tumor formation in the rest parts of the stomach. Therefore, even after curative endoscopic resection, regular follow-up endoscopy is necessary to look for metachronous gastric cancer. Endoscopic resection, which preserves the entire stomach, improves the quality of life, causes lesser complications, requires a shorter hospital stay, and is more cost-effective than surgical resection.⁹³⁻⁹⁸ In conclusion, we recommend endoscopic resection as the first line of treatment for well or moderately differentiated tubular or papillary

gastric adenocarcinoma measuring ≤ 2 cm in diameter without endoscopic signs of ulcer and submucosal invasion since endoscopic resection is comparable to surgical resection in terms of survival, is associated with a satisfactory quality of life, and is economical.⁹³⁻⁹⁶

Statement G4

We suggest endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma with the following endoscopic findings: (1) mucosal cancer > 2 cm without ulcer, or (2) mucosal cancer ≤ 3 cm with ulcer (Grade of recommendation: weak, Level of evidence: moderate).

The World Health Organization histological classification of gastric cancer published in 2000 is widely accepted as the standard classification system for gastric cancer, which defines undifferentiated carcinoma as carcinomas without glandular differentiation and squamous epithelial differentiation. However, most studies on endoscopic resection have classified well or moderately differentiated tubular or papillary adenocarcinoma as differentiated type adenocarcinoma and poorly differentiated tubular adenocarcinoma and poorly cohesive carcinoma as undifferentiated type adenocarcinoma. Expansion of existing indications for endoscopic resection should be considered only if there is no difference in the survival rates between endoscopic resection and standard surgical treatment. In addition, surgery-related mortalities must be compared and reviewed to determine the permissible range of risk of lymph node metastasis. The risk of lymph node metastasis is generally estimated based on the size of tumor, histologic type and grade, depth of invasion, and presence or absence of lymphovascular invasion. The risk of lymph node metastasis and distant metastasis has been reported to be 0.0%–0.21% for well or moderately differentiated tubular or papillary gastric mucosal adenocarcinoma measuring > 2 cm without ulcers or mucosal cancer measuring ≤ 3 cm with ulcers if the endoscopically resected tumor shows a negative resection margin and no lymphovascular invasion. Considering that the risk of lymph node or distant metastasis (0.0%–0.21%) is similar to the mortality of gastrectomy (0.1%–0.3%), endoscopic resection may be considered for the lesions described above.⁹⁹⁻¹⁰¹ Additionally, studies reported no significant difference between the 5-year survival rate of surgical resection and endoscopic resection (92.0%–97.2% vs. 93.3%–96.4%), indicating that endoscopic resection is considered curative for the

aforementioned lesions with no requirement of further treatment.^{95,100,102-109}

Surgical resection is the standard treatment for clinically suspected submucosal invasive gastric cancer in preoperative evaluation. However, studies analyzing pathologic results of patients who underwent gastrectomy due to preoperatively suspected submucosal invasion reported that 28.8%–43.0% of these lesions could have been treated with endoscopic resection.^{110,111} Therefore, further research is needed regarding treatment methods for preoperatively suspected submucosal invasive early gastric cancer.

Statement G5

We suggest endoscopic resection for poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, or signet ring cell carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤ 2 cm, endoscopically mucosal cancer, and no ulcer in the tumor (Grade of recommendation: weak, Level of evidence: low).

Undifferentiated type adenocarcinoma including poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma and signet ring cell carcinoma of the stomach has not been accepted as an indication for endoscopic resection due to reports that undifferentiated type adenocarcinoma is associated with a high risk of lymph node metastasis.^{112,113} However, retrospective studies reported a low incidence of extra-gastric metastasis during follow-up and high 5-year survival rates of 95.0%–98.6% among patients who underwent endoscopic resection for undifferentiated type adenocarcinoma with mucosal invasion, no ulcer and ≤ 2 cm in size.^{100,114-118} Studies also reported no significant difference in long-term outcomes between endoscopic resection and surgical resection for the aforementioned lesions.^{95,100,103,118} Thus, endoscopic resection may be recommended for undifferentiated type gastric adenocarcinoma with mucosal invasion, no ulcer and ≤ 2 cm in size. However, since undifferentiated type adenocarcinoma tends to have unclear borders that contribute to low curative resection rates (45.1%–70%),^{115,116} it is important to clearly identify borders and secure a sufficient resection margin during endoscopic resection. In addition, even in undifferentiated type adenocarcinoma, poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma and signet ring cell carcinoma can have different biological behaviors, and further studies in this field are needed.

Statement G6

We recommend prophylactic hemostasis of visible vessels on the post-resection ulcer caused by endoscopic resection of early gastric cancer to lower the risk of delayed bleeding (Grade of recommendation: strong, Level of evidence: low).

Statement G7

We recommend proton pump inhibitors to decrease the risk of symptoms and complications associated with iatrogenic ulcers caused by endoscopic resection of early gastric cancer (Grade of recommendation: strong, Level of evidence: high).

Reports on the incidence of bleeding associated with endoscopic resection vary depending on the definition of bleeding. Serious immediate bleeding that requires an intra-procedural blood transfusion or surgical treatment has been reported in $< 1\%$ of patients.¹¹⁹ Delayed bleeding that occurs after endoscopic resection is defined as bleeding from an iatrogenic ulcer that requires hemostasis, and its incidence has been reported to be 1.3%–11.9%. Delayed bleeding usually occurs within 24 hours after endoscopic resection but can occur up to 2 weeks after endoscopic resection.^{120,121} Prophylactic coagulation of visible vessels exposed on the base of an iatrogenic ulcer after endoscopic resection can effectively prevent delayed bleeding. One retrospective study reported a 2.47-fold increase in the risk of delayed bleeding when prophylactic coagulation was not performed.¹²² However, excessive prophylactic coagulation can increase the risk of post-coagulation syndrome or delayed perforation.^{123,124}

Postoperative administration of proton pump inhibitors or histamine 2 (H₂) receptor blockers can prevent delayed bleeding. Whether one drug is more effective than the other is unclear with some studies reporting proton pump inhibitors to be more effective in treating iatrogenic ulcers related to endoscopic resection,^{125,126} and others reporting the two drugs to be on a par with one another.^{127,128} One meta-analysis reported no difference between proton pump inhibitors and H₂ receptor blockers in their ability to treat iatrogenic ulcers and relieve symptoms but reported a significantly lower incidence of delayed bleeding in patients who were administered proton pump inhibitors (OR, 0.49; 95% CI, 0.25–0.95).¹²⁹ Various reports regarding the dose and administration period of proton pump inhibitors for iatrogenic ulcers and concomitant use of mucosal protective agents are available.¹³⁰⁻¹⁴² Randomized trials reported that administration of proton pump inhibitors before endoscopic resection is not effective in preventing de-

layed bleeding and that second look endoscopy also did not effectively prevent delayed bleeding.¹⁴³⁻¹⁴⁵

Statement G8

We recommend endoscopic closure as the first treatment option for perforation that occurred during endoscopic resection of early gastric cancer (Grade of recommendation: strong, Level of evidence: low).

The incidence of perforation resulting from excessive damage to the muscularis propria during endoscopic resection is 1.2%–5.2% and that of delayed perforation that occurs after endoscopic resection is reported at below 0.5%. The risk of intraoperative perforation varies depending on the location and size of the lesion.¹⁴⁶ Closure by endoscopic clipping effectively treats intraoperative perforation, and conservative treatments such as fasting and antibiotic administration after successful endoscopic closure usually lead to symptom relief without the need for additional surgical treatments.¹⁴⁷⁻¹⁴⁹ However, surgical treatment must be considered in case of unsuccessful closure, signs of generalized peritonitis, or delayed perforation.¹⁵⁰ The endoscopic closure must be performed by an experienced endoscopist. If a patient becomes hemodynamically unstable or has respiratory problems due to tension pneumoperitoneum, rapid decompression of the intra-abdominal pressure using a percutaneous aspiration and/or drainage of intra-abdominal free air is required.¹⁵¹ It may also be useful to switch from oxygen to carbon dioxide infusion during endoscopy when perforation occurs.¹⁵²

Statement G9

We recommend surgical gastrectomy if histopathological evaluation after endoscopic resection of early gastric cancer meets the criteria for non-curative resection. An exception applies if cancer invasion is observed at the horizontal resection margin only (Grade of recommendation: strong, Level of evidence: moderate).

Statement G10

We recommend additional endoscopic management rather than surgical gastrectomy if histopathological evaluation of endoscopically resected early gastric cancer specimen shows positive involvement at the horizontal resection margin without any other findings compatible with non-curative resection (Grade of recommendation: strong, Level of evidence: moderate).

Curative resection of an absolute indication lesion is assumed when well or moderately differentiated tubular or papillary adenocarcinoma confined to the mucosa measuring <2 cm with no histopathological evidence of lymphovascular invasion and ulcers and a negative resection margin is observed following endoscopic *en bloc* resection of a lesion. Curative resection of an expanded indication lesion is considered when any of the following conditions are observed after *en bloc* resection: (1) differentiated type mucosal adenocarcinoma such as well or moderately differentiated tubular or papillary adenocarcinoma with a negative resection margin and ulcers of ≥ 2 cm and without lymphovascular invasion; (2) mucosal adenocarcinoma of ≤ 3 cm accompanied by ulcers; (3) submucosal invasive cancer of ≤ 3 cm with submucosal invasion depth ≤ 500 μm ; or (4) undifferentiated type adenocarcinoma such as poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, and signet ring cell carcinoma measuring ≤ 2 cm confined to the mucosa. Lesions that do not meet these criteria for curative resection are considered to have undergone non-curative resection.^{1,120,153} The risk of lymph node metastasis is reported to be 2.6%–3.0% for differentiated type adenocarcinoma that satisfy the criteria for non-curative resection, with the exception of differentiated type adenocarcinoma with a positive horizontal resection margin, and 5%–20% for undifferentiated type adenocarcinoma.^{90,154,155} In a large-scale cohort study on patients who received additional surgical treatments due to non-curative resection, lymphatic invasion was associated with the highest risk of lymph node metastasis. Large tumor size, positive vertical resection margin, vascular invasion, and submucosal invasion depth > 500 μm are reported to increase the risk of lymph node metastasis to a similar extent.¹⁵⁶ Many studies have demonstrated that lymphovascular invasion is an important risk factor of lymph node metastasis.¹⁵⁷⁻¹⁵⁹ Considering the risk of lymph node metastasis, patients may require additional surgical gastrectomy including regional lymphadenectomy when they satisfy the criteria for non-curative resection, with the exception of having a positive horizontal resection margin only. Differentiated type mucosal adenocarcinomas less than 2 cm in size that show lymphovascular invasion are reported to have low risk of lymph node metastasis, in which case the need for additional surgical procedures is not clear.¹⁶⁰ Although some studies comparing surgical resection following non-curative resection vs. no surgery reported no additional benefits of additional surgery,¹⁶¹⁻¹⁶³ most retrospective studies have reported an increase in overall survival and disease-specific survival in pa-

tients who underwent surgical resection.^{158,159,164-167} Furthermore, additional surgical resection following non-curative endoscopic resection has also been reported to increase survival among patients of advanced age.¹⁶⁸⁻¹⁷⁰

Differentiated type adenocarcinoma with a positive horizontal resection margin that meet all the other criteria for curative resection following *en bloc* resection is associated with a low risk of lymph node metastasis. A cohort study that followed up patients who had this type of cancer and did not receive additional treatments reported low 5-year recurrence rates among these patients and that recurrent tumors could be curatively treated without any mortality associated with gastric cancer.¹⁷¹ Therefore, additional endoscopic resection or argon plasma coagulation treatment may be used instead of surgical resection for tumors with a positive horizontal resection margin. Retrospective cohort studies reported favorable prognoses following these endoscopic treatments and suggested that additional endoscopic treatments within 3 months after the initial endoscopic resection are associated with low recurrence rates.¹⁷²⁻¹⁷⁴ However, it is impossible to determine whether resection is curative following argon plasma coagulation since histological evaluation is impossible; thus, a close follow-up is required after argon plasma coagulation.

Statement G11

We recommend *Helicobacter pylori* eradication treatment after endoscopic resection of early gastric cancer in *H. pylori*-infected patients (Grade of recommendation: strong, Level of evidence: high).

H. pylori eradication may be considered for patients who test positive for *H. pylori* following an endoscopic treatment of early gastric cancer to reduce the risk of metachronous recurrence. Fukase et al.¹⁷⁵ reported that *H. pylori* eradication significantly reduced the risk of metachronous gastric cancer in patients with early gastric cancer after endoscopic resection in their multicenter randomized controlled study in 2008 (hazard ratio [HR], 0.339; 95% CI, 0.157–0.729). Based on this study, most clinical practice guidelines recommend *H. pylori* eradication after endoscopic resection of early gastric cancer.¹⁷⁶⁻¹⁸⁰ Four meta-analyses investigating whether *H. pylori* eradication after endoscopic resection of early gastric cancer prevents metachronous gastric cancer reported that *H. pylori* eradication significantly reduces the risk of metachronous gastric cancer to 0.42–0.51.¹⁸¹⁻¹⁸⁴ A Korean prospective randomized double-blind, placebo-controlled trial published in

2018 also showed that 50% and 68% of metachronous gastric cancer was reduced in patients who received eradication therapy and for those in whom eradication was successful after endoscopic treatment of early gastric cancer, respectively.¹⁸⁵ Another Korean prospective randomized study published in 2018 reported a 2.02-fold increase in the risk of metachronous gastric cancer in the control group compared with the eradication group.¹⁸⁶ Therefore, we recommend *H. pylori* eradication following endoscopic resection of early gastric cancer for prevention of metachronous gastric cancer.

Statement G12

We recommend regular surveillance endoscopy every 6–12 months for patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria for early detection of metachronous gastric cancer (Grade of recommendation: strong, Level of evidence: low).

Surveillance strategy for the patients after endoscopic resection has similar follow-up plans compared with those after surgical gastrectomy. However, more careful follow-up should be performed after endoscopic resection of early gastric cancer as it is associated with high incidence of synchronous multiple gastric cancers and metachronous gastric cancers. The Korean clinical practical guideline for gastric cancer recommends patients who undergo endoscopic treatment for early gastric cancer to have a follow-up endoscopic examination on a yearly basis.¹⁸⁷ The Japanese guideline for endoscopic resection for early gastric cancer recommend an endoscopy examination at a 6- to 12-month interval following curative endoscopic resection to detect metachronous gastric cancer and additionally for those with expanded curative criteria recommend ultrasonography or CT—also at 6- to 12-month interval—to detect possible metastasis.^{7,120} The ESGE guidelines for ESD recommend undergoing the first endoscopic surveillance at 3–6 months after curative endoscopic resection, and regular endoscopic examinations on a yearly basis thereafter.¹ They recommend considering staging abdominal CT scan for expanded indication lesions.¹

The purpose of follow-up examinations after endoscopic resection is to detect local recurrence at the resection site, synchronous or metachronous gastric cancer, and extra-gastric metastases. One meta-analysis reported the incidence of local recurrence following endoscopic treatment to be 0.3% for ESD and 5.2% for EMR.⁴⁹ A Korean multicenter prospective study published in 2018 reported the incidence of local recurrence

to be 0.7% in patients who had curative ESD and 2.4% who had non-curative ESD.¹⁸⁸ Thus, since the incidence of local recurrence following curative ESD is below 1%, detecting synchronous or metachronous gastric cancer must be prioritized before detecting local recurrences. Since patients with early gastric cancer who receive endoscopic resection have most of their gastric mucosa intact, they are more prone to developing metachronous and synchronous gastric cancers compared with those after surgical gastrectomy. If synchronous cancer is defined as cancer detected within 1 year after an endoscopic resection, and metachronous cancer as cancer detected starting 1 year after an endoscopic resection, the incidence of the respective cancers is reported to be 0.87%–11.0% and 3.6%–22.7%.^{101,189-191} A Japanese study published in 2015 reported the incidence of metachronous recurrence to increase to 9.5%, 13.1%, and 22.7% at 5, 7, and 10 years, respectively, after curative ESD.¹⁹¹ Another Japanese multicenter study reported the annual average incidence of metachronous gastric cancer to be 3.5%.¹⁸⁹ A recently conducted Korean study reported that the annual average incidence of synchronous and metachronous gastric cancer is 2.47%, and that patients who had follow-up examinations for over 1 year were significantly more likely to require surgery for metachronous cancer than patients who underwent follow-up examinations for ≤ 1 year.¹⁹² Based on these results, early detection of metachronous and synchronous gastric cancer that develops after endoscopic resection is crucial for a successful follow-up. Patients must undergo follow-up endoscopy every 6–12 months within 5 years after an endoscopic resection for the detection of local recurrence and metachronous or synchronous cancer. It is advisable to continue undergoing follow-up endoscopy after the 5-year mark as the risk of metachronous gastric cancer consistently increases even after 5 years.^{191,193} Further research is needed to establish more detailed and precise standards regarding the interval and duration of follow-up surveillance endoscopy.

Statement G13

We suggest regular abdominopelvic CT scan of 6- to 12-month interval for detection of extra-gastric recurrence after curative endoscopic resection of early gastric cancer based on absolute and expanded criteria (Grade of recommendation: weak, Level of evidence: low).

Very few clinical practice guidelines on follow-up abdominopelvic CT scan for endoscopic resection of early gastric cancer are available. Japanese guidelines recommend routine ultra-

sounds or CT at a 6- to 12-month interval for lesions meeting expanded criteria,^{7,120} and ESGE guideline recommends to consider staging abdominopelvic CT for lesions meeting expanded criteria.¹ A Korean study published in 2015 reported lymph node metastases 5 and 4 years after curative resection in two patients with absolute and expanded criteria lesions, respectively.¹⁰¹ In another Korean study on 15 cases of extra-gastric recurrence published in 2017, 66.7% (4/6) of expanded criteria lesions and 83.3% (5/6) of out-of-indication lesions showed extra-gastric recurrences on CT without any intragastric recurrences, demonstrating the need for follow-up CT in patients with expanded criteria lesions.¹⁹⁴

However, another Korean study reported detecting extra-gastric lymph node recurrence on CT in only two (one case of absolute criteria and one of expanded criteria) among total of 2,182 patients who underwent curative endoscopic resection, suggesting that CT after curative endoscopic resection is unnecessary for patients who meet expanded criteria considering the cost and radiation dose of CT.¹⁹⁵ In addition, a study that followed up 894 mucosal cancers using endoscopy and abdominopelvic CT following their curative endoscopic resection reported CT signs of recurrence in only two cases, suggesting that CT plays a minimal role in follow-up after endoscopic resection.¹⁹⁶ Precise standards for the target subjects and interval of follow-up abdominopelvic CT are yet to be established, and further research is needed in this regard.

EARLY COLORECTAL CANCER

Statement C1

Poor histologic types (poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma), deep submucosal invasion, lymphovascular invasion, and intermediate-to-high-grade tumor budding at the site of deepest invasion are risk factors of lymph node metastasis in early colorectal cancer (Grade of recommendation: strong, Level of evidence: moderate).

Predicting the risk of potential lymph node metastasis of early colorectal cancer affects the decision of whether to additionally perform a radical surgery following endoscopic or surgical local excision of early colorectal cancer. Histologic grades are a traditional predictor of lymph node metastasis of early colorectal cancer. Poor histologic types (poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma) are associated with a higher risk of lymph node

metastasis than moderately-to-well differentiated adenocarcinoma, and the risk of metastasis increases in proportion to the histologic grade.¹⁹⁷⁻²⁰² Multivariate analyses have shown that poor histologic types (poorly differentiated adenocarcinoma, signet ring cell carcinoma, mucinous carcinoma) have increased ORs (2.93–45.9) for lymph node metastasis compared with well differentiated adenocarcinomas.²⁰³⁻²⁰⁵ Four meta-analyses also showed early colorectal cancers with poor histologic types to have an increased risk of lymph node metastasis with ORs ranging between 4.78 and 8.27.^{8,206-208}

Well differentiated intramucosal colorectal cancer does not metastasize to the lymph nodes, whereas 6%–20% of early colorectal cancers that invade the submucosa metastasize to the lymph nodes.^{8,206-209} In studies using the relative depth of submucosal invasion, pedunculated polyps are classified according to the Haggitt classification, and nonpedunculated polyps are classified using the Kudo or Kikuchi classification based on the depth of invasion.²¹⁰⁻²¹² The risk of lymph node metastasis increases in proportion to the depth of submucosal invasion determined by these classification methods (Haggitt level 4 and Kudo sm2-3).^{197-199,205,209,213,214} In studies that measured the absolute depth of submucosal invasion from the muscularis mucosa and evaluated the risk of lymph node metastasis, depth of vertical invasion of $\geq 1,000$ μm of nonpedunculated cancer were associated with the risk of lymph node metastasis, and the risk increased in proportion to the depth of invasion.^{201,203,215-219} In meta-analyses evaluating the risk of lymph node metastases in colorectal cancer, depth of submucosal invasion of $\geq 1,000$ μm increased the OR of lymph node metastasis to 3.0–5.93.^{8,206-208} However, the risk of metastasis based on the absolute depth of submucosal invasion has a relatively low predictive power.^{8,201} For this reason, the width of invasion has been also used as a quantitative measure of the risk of lymph node metastasis to complement the absolute depth of invasion.

In many studies including multivariate analyses, lymphovascular invasion was an independent risk factor for predicting local lymph node metastasis.^{198-205,220} There have been five meta-analyses that evaluated the risks for lymph node metastasis according to lymphatic and vascular invasion; lymphatic invasion (OR, 4.15–6.91), vascular invasion (OR, 2.20–4.03), and lymphovascular (either lymphatic or vascular) invasion (OR, 3.9–5.47) all had increased lymph node metastases.^{8,206-208,221}

Tumor budding is defined as the presence of a single tumor cell or a cluster of < 5 tumor cells at the tumor-invasive front of

resected specimens.^{222,223} The definition of tumor budding varies between studies, but tumor budding is generally classified as intermediate-to-high if ≥ 5 tumor buds are observed. Intermediate-to-high grade tumor budding is associated with an increased risk of lymph node metastasis.^{198,201,219,224,225} According to some meta-analyses, the presence of tumor budding increases the OR of lymph node metastasis by 3.26- to 7.74-fold.^{8,206-208,221,223} A recent large-scale, multi-institutional Japanese study suggests that poorly differentiated clusters at the invasive front are also a useful histologic predictor of lymph node metastasis.^{201,225} Poorly differentiated clusters are composed of ≥ 5 cancer cells present at invasive front of the tumor that lack full glandular formation. Therefore, compared with tumor budding, poorly differentiated clusters are more easily recognized in hematoxylin and eosin staining and do not require auxiliary immunohistochemical staining.

Statement C2

Endoscopic resection of submucosal colorectal cancer with a high risk of lymph node metastasis has a higher recurrence rate than surgical resection. Therefore, we recommend additional surgery if histological signs after endoscopic resection suggest a high risk of lymph node metastasis (Grade of recommendation: strong, Level of evidence: high).

Early colorectal cancer confined to the mucosa of the large intestine does not metastasize to the lymph nodes. Thus, complete endoscopic resection of a primary tumor eliminates the possibility of recurrence, and no further treatment is required in case of mucosal colorectal cancer. A population-based study conducted in the United States reported no difference in the 5-year survival rate between endoscopic resection and surgical treatment for mucosal or submucosal colorectal cancers (\leq stage 1) with a longest diameter of ≤ 4 cm.²²⁶ Mounzer et al.²²⁷ also reported no difference in 5-year colorectal cancer-specific recurrence-free survival rates (97.6% vs. 97.5%; $P = 0.75$) and colorectal cancer-specific mortalities (HR, 1.10; 95% CI, 0.72–1.69; $P = 0.65$) between endoscopic resection and surgical treatment for colorectal cancer confined to the mucosa.

However, one study has reported significantly lower recurrence-free survival rates and higher colorectal cancer-specific mortalities for endoscopic resection of submucosal colorectal cancer than for surgical treatment (HR, 2.40; 95% CI, 1.75–3.29; $P < 0.001$).²²⁷ In addition, studies comparing endoscopic resection and surgical resection for submucosal colorectal cancer reported local recurrence rates of 2.3%–6.4% for endo-

scopic resection²²⁸⁻²³⁰ and relatively low local recurrence rates of 0.9%–1.87% for surgical resection.²²⁸⁻²³⁰ Prognoses after endoscopic and surgical resection depend on whether the submucosal colorectal cancer is associated with a high risk of lymph node metastasis. A Korean study conducted in 2014 reported no difference between endoscopic resection and surgical resection in the mean 37 months (range, 6–98 months) cumulative incidence of recurrence in case of mucosal and superficial submucosal colorectal cancer with low risks of lymph node metastasis ($P=0.641$).²³¹ Yoda et al.²³² reported a high 5-year recurrence-free survival rate of 98% for low-risk submucosal colorectal cancer. Conversely, early colorectal cancer accompanied by risk factors of lymph node metastasis was associated with a significantly higher incidence of lymph node metastasis (15.5%) as opposed to when early colorectal cancer was not accompanied by the risk factors (7.1%) ($P=0.001$).²²⁹ In another Japanese study,²³² higher 5-year recurrence-free survival rates were observed in patients with high-risk, early submucosal colorectal cancer who underwent additional surgery after endoscopic treatment than in those who did not undergo additional surgery (97% vs. 89%; $P=0.130$). Succeeding studies have reported high recurrence rates and significantly lower survival rates for early colorectal cancer accompanied by risk factors of lymph node metastasis that was treated endoscopically only.²³³⁻²³⁵ Thus, although endoscopic resection effectively treats mucosal colorectal cancer and submucosal colorectal cancer without the risk factors of lymph node metastasis, additional surgery should be considered for submucosal colorectal cancer with the risk factors of lymph node metastasis.

Statement C3

We recommend endoscopic assessment of pit patterns and vascular patterns to estimate the depth of submucosal invasion before endoscopic resection of early colorectal cancer (Grade of recommendation: strong, Level of evidence: high).

Submucosal colorectal cancer accompanied by risk factors of lymph node metastasis requires surgery. Many studies have investigated the association between the depth of submucosal invasion, which is a risk factor for lymph node metastasis, and endoscopic features. Estimating the depth of invasion prior to treatment of early colorectal cancer is essential for choosing the appropriate method of surgical or endoscopic treatment, and this can be done using magnifying chromoendoscopy and NBI.

Kudo’s pit pattern classification is useful for estimating the depth of submucosal invasion in early colorectal cancer (Table 5). Type V, especially V_N pit pattern observed by magnifying chromoendoscopy indicates a high possibility of deep submucosal invasion.²³⁶⁻²³⁸ Studies analyzing the pit patterns of lesions suspected as early colorectal cancer reported the incidence of submucosal invasion to be mere 1%, 5%, and 8% for type III_L, III_S, and IV pit patterns, respectively, but 14% for type V_I and 80% for type V_N.²³⁹ The sensitivity of pit patterns in estimating the depth of submucosal invasion varies depending on the macroscopic appearance of the lesions. The diagnostic accuracy of pit pattern for deep submucosal invasion in polypoid, flat, and depressed lesions was 75.8%, 85.7%, and 98.6%, respectively, and are thus useful for diagnosing deep submucosal colorectal cancer and selecting an appropriate treatment method.²⁴⁰ A meta-analysis on 17 studies that analyzed the diagnostic performance of magnifying chromoendoscopy reported magnifying chromoendoscopy to have 81% sensitivity and 95% specificity in diagnosing deep submucosal invasion.¹⁵ A meta-analysis on nine studies including three abstracts in which magnifying chromoendoscopy had 84% sensitivity and 97% specificity confirmed the diagnostic usefulness of magnifying chromoendoscopy.²⁴¹ Indigo carmine and crystal violet are commonly used in magnifying chromoendoscopy with no significant difference in diagnostic accuracy between the two.¹⁵

NBI is used to examine the microvascular architecture and

Table 5. Kudo’s Pit Pattern for the Endoscopic Diagnosis of Colorectal Neoplasia²³⁸

Pit pattern classification	Type I	Type II	Type III _S	Type III _L	Type IV	Type V _I	Type V _N
Description	Round (normal) pits	Asteroid pits	Tubular or round pits, smaller than the normal pits	Tubular or round pits, larger than normal pits	Branched or gyrus-like pits	Irregular arrangement and sizes of type III _S , III _L , IV pit patterns	Amorphous or non-structural pit patterns
Most likely histology	Normal	Hyperplastic polyp Sessile serrated lesion	Adenoma Intramucosal carcinoma	Adenoma	Adenoma Intramucosal carcinoma	Intramucosal cancer Superficial submucosal cancer	Deep submucosal cancer

surface structure. NBI findings suggesting deep submucosal invasion are as follows: completely unclear or amorphous surface pattern, severely irregular thickness and arrangement of capillary vessels, and avascular or loose microvessel areas.²⁴²⁻²⁴⁴ Several NBI classification systems have been proposed to aid optical diagnosis of colorectal tumors, such as Sano's classification, Hiroshima's classification, and later, NBI International Colorectal Endoscopic (NICE) classification, and the Japan NBI Expert Team (JNET) classification (Table 6). The sensitivity, specificity, and accuracy of Sano IIIA/IIIB for differentiating intramucosal/superficial submucosal cancer from deep submucosal cancer are 85%, 89%, and 88%, respectively.²⁴⁵ The diagnostic sensitivity, specificity, and accuracy of Hiroshima class C3 patterns for deep submucosal cancer are 67%, 99%, and 93% with excellent interobserver and intraobserver agreement ($\kappa=0.749$ and $\kappa=0.745$, respectively).²⁴⁶ JNET type III had diagnostic sensitivity, specificity, and accuracy of 55.4%, 99.8%, 96.6%, respectively.^{247,248} In a meta-analysis on 13 studies on the accuracy of NBI in diagnosing deep submucosal cancer, NBI had 77% sensitivity and 98% specificity.¹⁵ A recent meta-analysis on 17 studies including three abstracts reported NBI to have 74% sensitivity and 98% specificity,²⁴¹ demonstrating that NBI accurately estimates the deep submucosal invasion in early colorectal cancer.

In addition to pit patterns and surface microvascular changes, the hardness of a lesion, deep and irregular depression on the tumor surface, absence of changes in the tumor shape upon air inflation, fold convergence toward the tumor, and non-lifting signs (the submucosa below the lesion does not lift when a solution is injected into the submucosa) are macroscopic signs of deep submucosal cancer.^{249,250} The non-lifting sign is reported to indicate submucosal fibrosis or deep submucosal invasion,²⁵¹ but it has lower sensitivity and accuracy

in predicting deep submucosal cancer than other macroscopic endoscopic findings associated with deep submucosal invasion.²⁵² Thus, to date, there is insufficient evidence to prove that non-lifting sign is a highly useful predictor of deep submucosal invasion. In a meta-analysis on six studies assessing the accuracy of macroscopic appearance in predicting deep submucosal cancer, macroscopic appearance had 80%–98% specificity but only 18%–66% sensitivity.¹⁵ Therefore, magnifying chromoendoscopy and NBI may be more useful for predicting deep submucosal cancer than macroscopic appearance.¹⁵

A meta-analysis comparing the accuracy of magnifying chromoendoscopy and NBI in predicting deep submucosal cancer reported no difference in sensitivity (magnifying chromoendoscopy 81% vs. NBI 77%, $P=0.41$) and specificity (95% vs. 98%, $P=0.09$) between the two techniques. In a recent meta-analysis on 17 studies including three abstracts, there was no difference in specificity between magnifying chromoendoscopy and NBI, but magnifying chromoendoscopy had a higher sensitivity (84% vs. 74%, $P<0.01$).²⁵³ A questionnaire survey conducted among 30 experts on magnifying and image-enhanced endoscopy showed that magnifying chromoendoscopy is superior to NBI in predicting deep submucosal cancer (88% vs. 83%, $P=0.0013$).²⁵³ However, since most of the studies included in these meta-analyses were conducted in Korea and Japan, further research is needed.

In conclusion, for macroscopic signs of deep submucosal invasion, Kudo VN pit patterns, Sano IIIB, Hiroshima C3, and JNET type 3, the risk of deep submucosal invasion is high and primary surgery should be performed. Whereas the pit patterns and the NBI findings have excellent specificity, the sensitivity is relatively low in diagnosing deep submucosal invasion. They may have excellent diagnostic accuracy, but are not substitutes for histopathological features. Thus, if a lesion with

Table 6. JNET Classification for the Endoscopic Diagnosis of Colorectal Neoplasia²⁴⁶

JNET classification	JNET 1	JNET 2A	JNET 2B	JNET 3
Vessel pattern	Invisible	Regular caliber Regular distribution (meshed or spiral pattern)	Variable caliber Irregular distribution	Loose vessel areas Interruption of thick vessels
Surface pattern	Regular dark or white spots Similar to surrounding normal mucosa	Regular (tubular/branched/papillary)	Irregular or obscure	Amorphous area
Most likely histology	Hyperplastic polyp Sessile serrated lesion	Low-grade intramucosal neoplasia	High-grade intramucosal neoplasia Superficial submucosal invasive cancer	Deep submucosal invasive cancer

JNET, Japan narrow band imaging (NBI) Expert Team.

high risk features for deep submucosal invasion can be safely and easily resected by endoscopy, endoscopic resection can be tried first and the need for further surgery may be determined based on histopathologic findings of endoscopic resection specimen.

Statement C4

En bloc and histologically complete resection should be achieved for endoscopic treatment of a suspected or established early colorectal cancer. We recommend ESD for the treatment of endoscopically resectable early colorectal cancer which cannot be resected *en bloc* using EMR technique (Grade of recommendation: strong, Level of evidence: moderate).

Deep submucosal invasion, poor histologic types (poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma), lymphovascular invasion, tumor budding/poorly differentiated clusters are risk factors of lymph node metastasis from early colorectal cancer. Additional surgery is required when any of these histopathological signs or histologically incompletely resected submucosal cancer such as positive vertical resection margin is observed following endoscopic resection. *En bloc* resection is important for assessing the need for additional surgery as it increases the rate of curative resection of early colorectal cancer and allows accurate histopathologic evaluation.^{49,254-260} In a meta-analysis on studies comparing between ESD and EMR of colorectal lesions conducted by Fujiya et al. in 2015, the rate of *en bloc* resection was 91.7% for ESD and 46.7% for EMR with an OR of 6.84 (95% CI, 3.30–14.18); ESD had a higher *en bloc* resection rate than EMR. In the same study, the rate of curative resection was also significantly higher for ESD (80.3%) than for EMR (42.3%) with an OR of 4.26 (95% CI, 3.77–6.57).²⁵⁷ In a meta-analysis on studies comparing ESD and EMR for sessile colorectal lesions measuring ≥ 20 mm conducted by Arezzo et al. in 2016, the rate of *en bloc* resection was 89.9% for ESD and 34.9% for EMR with a relative risk of 1.93 (95% CI, 1.46–2.54).²⁵⁸ Additionally, the rate of R0 resection was 79.6% for ESD and 36.2% for EMR with a relative risk of 2.01 (95% CI, 1.76–2.29). Based on these results, Arezzo et al.²⁵⁸ concluded that ESD is superior to EMR for *en bloc* resection and R0 resection of sessile colorectal lesions measuring ≥ 20 mm.

Reports on the complications of colon polypectomy including bleeding and perforation have varied between studies.²⁵⁷⁻²⁵⁹ One meta-analysis reported the incidence of perfora-

tion to be higher for ESD (4.0%–5.7%) than for EMR (0.8%–1.4%).²⁵⁹ Most complications occurring after ESD can be treated endoscopically, and <1% of all colorectal lesions require surgery due to complications of ESD; therefore, ESD is acceptably safe considering the high efficacy of the procedure.²⁶¹ However, the risk of complications and the rate of *en bloc* or curative resection significantly depend on the operator's level of experience since ESD of colorectal lesions is more difficult to perform than other polypectomy methods of colorectal lesions.^{262,263} Therefore, physicians experienced in therapeutic endoscopy after sufficient training of ESD must perform colorectal ESD in clinical settings where they can cope with emergency situations due to ESD-related complications.²⁶²⁻²⁶⁶

CONCLUSION

Endoscopic resection of early gastrointestinal cancer causes fewer adverse events, requires a shorter hospital stay, does not require bowel resection, and is more economical than surgical resection. However, endoscopic resection is not indicated for all patients with early gastrointestinal cancer. It is important to select patients with early gastrointestinal cancer that can be treated by endoscopic resection. Furthermore, excellent long-term outcomes can be ensured only via appropriate post-resection care such as additional surgery if necessary and regular follow-up after endoscopic resection. This clinical practice guideline proposes a standard treatment process for gastroenterologists performing endoscopic resection, thereby contributing to the prevention of unnecessary health care or inappropriate treatments and to the provision of relevant clinical recommendations for endoscopic resection of early gastrointestinal cancer.

ADDITIONAL INFORMATION

Funding Source

This guideline project was financially supported by Korean Society of Gastrointestinal Endoscopy (KSGE).

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Author Contribution

Conceptualization: Cho JY, Lee ST, Chun HJ. Data curation: Kim Jie-Hyun, Kim Ji Hyun, Min YW, Lee SH, Bae JH, Chung

H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS. Investigation: Kim Jie-Hyun, Kim Ji Hyun, Min YW, Lee SH, Bae JH, Chung H, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS. Project administration: Choi M, Park DA. Supervision: Choi KD, Lee HS, Choi M, Park DA, Park CG. Writing - original draft: Park CH, Yang DH. Writing - review & editing: Kim JW, Lee JY, Byeon JS. Approval of final manuscript: all authors

ORCID

Park CH	https://orcid.org/0000-0003-3824-3481
Yang DH	https://orcid.org/0000-0001-7756-2704
Kim JW	https://orcid.org/0000-0003-0505-2697
Kim JH	https://orcid.org/0000-0002-9198-3326
Kim JH	https://orcid.org/0000-0003-0861-2792
Min YW	https://orcid.org/0000-0001-7471-1305
Lee SH	https://orcid.org/0000-0001-7221-7506
Bae JH	https://orcid.org/0000-0001-7669-1213
Chung H	https://orcid.org/0000-0001-5159-357X
Choi KD	https://orcid.org/0000-0002-2517-4109
Park JC	https://orcid.org/0000-0001-8018-0010
Lee H	https://orcid.org/0000-0003-4271-7205
Kwak MS	https://orcid.org/0000-0002-8988-7423
Kim B	https://orcid.org/0000-0002-0039-7728
Lee HJ	https://orcid.org/0000-0003-2764-9339
Lee HS	https://orcid.org/0000-0002-1667-7986
Choi M	https://orcid.org/0000-0002-2424-9965
Park DA	https://orcid.org/0000-0001-7225-3152
Byeon JS	https://orcid.org/0000-0002-9793-6379
Park CG	https://orcid.org/0000-0002-9581-2655
Cho JY	https://orcid.org/0000-0002-7182-5806
Lee ST	https://orcid.org/0000-0002-0758-1923
Chun HJ	https://orcid.org/0000-0002-5539-361X

Supplementary Material

Supplementary materials are available at the Intestinal Research website (<https://www.irjournal.org>).

REFERENCES

1. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2015;47: 829-854.
2. Eom BW, Jung KW, Won YJ, Yang H, Kim YW. Trends in gastric cancer incidence according to the clinicopathological characteristics in Korea, 1999-2014. *Cancer Res Treat* 2018; 50:1343-1350.
3. Kim SG, Lyu DH, Park CM, et al. Current status of endoscopic submucosal dissection for early gastric cancer in Korea: role and benefits. *Korean J Intern Med* 2019;34:785-793.
4. Miyamoto S, Muto M, Hamamoto Y, et al. A new technique for endoscopic mucosal resection with an insulated-tip electro-surgical knife improves the completeness of resection of intramucosal gastric neoplasms. *Gastrointest Endosc* 2002; 55:576-581.
5. Bok GH, Cho JY. ESD Hands-on course using ex vivo and in vivo models in South Korea. *Clin Endosc* 2012;45:358-361.
6. Park CH, Lee H, Kim DW, et al. Clinical safety of endoscopic submucosal dissection compared with surgery in elderly patients with early gastric cancer: a propensity-matched analysis. *Gastrointest Endosc* 2014;80:599-609.
7. Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017;20:1-19.
8. Bosch SL, Teerenstra S, de Wilt JH, Cunningham C, Nagtegaal ID. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. *Endoscopy* 2013;45:827-834.
9. Kim TJ, Kim ER, Hong SN, Kim YH, Chang DK. Current practices in endoscopic submucosal dissection for colorectal neoplasms: a survey of indications among Korean endoscopists. *Intest Res* 2017;15:228-235.
10. Ebi M, Shimura T, Yamada T, et al. Multicenter, prospective trial of white-light imaging alone versus white-light imaging followed by magnifying endoscopy with narrow-band imaging for the real-time imaging and diagnosis of invasion depth in superficial esophageal squamous cell carcinoma. *Gastrointest Endosc* 2015;81:1355-1361.
11. Ishihara R, Matsuura N, Hanaoka N, et al. Endoscopic imaging modalities for diagnosing invasion depth of superficial esophageal squamous cell carcinoma: a systematic review and meta-analysis. *BMC Gastroenterol* 2017;17:24.
12. Nagahama T, Yao K, Maki S, et al. Usefulness of magnifying endoscopy with narrow-band imaging for determining the horizontal extent of early gastric cancer when there is an unclear margin by chromoendoscopy (with video). *Gastrointest Endosc* 2011;74:1259-1267.
13. Kato M, Kaise M, Yonezawa J, et al. Magnifying endoscopy with narrow-band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. *Gastrointest Endosc* 2010;72:523-529.
14. Mocellin S, Marchet A, Nitti D. EUS for the staging of gastric

- cancer: a meta-analysis. *Gastrointest Endosc* 2011;73:1122-1134.
15. Backes Y, Moss A, Reitsma JB, Siersema PD, Moons LM. Narrow band imaging, magnifying chromoendoscopy, and gross morphological features for the optical diagnosis of T1 colorectal cancer and deep submucosal invasion: a systematic review and meta-analysis. *Am J Gastroenterol* 2017;112:54-64.
 16. Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, Version 2.2019, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2019;17:855-883.
 17. Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. *Esophagus* 2017;14:1-36.
 18. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj* 2019;366: l4898.
 19. Higgins JPT, Green S. *Cochrane handbook for systematic reviews of interventions*, version 5.1.0 [Internet]. c2011 [cited 2019 Jul 26]. <https://handbook-5-1.cochrane.org/>.
 20. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010;25:603-605.
 21. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529-536.
 22. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. *BMJ* 2008;336:1170-1173.
 23. Ajani JA, D'Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1.2015. *J Natl Compr Canc Netw* 2015;13:194-227.
 24. Endoscopic Classification Review Group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. *Endoscopy* 2005;37:570-578.
 25. Lee WC, Lee TH, Jang JY, et al. Staging accuracy of endoscopic ultrasound performed by nonexpert endosonographers in patients with resectable esophageal squamous cell carcinoma: is it possible? *Dis Esophagus* 2015;28:574-578.
 26. Thosani N, Singh H, Kapadia A, et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. *Gastrointest Endosc* 2012;75:242-253.
 27. Dhupar R, Rice RD, Correa AM, et al. Endoscopic ultrasound estimates for tumor depth at the gastroesophageal junction are inaccurate: implications for the liberal use of endoscopic resection. *Ann Thorac Surg* 2015;100:1812-1816.
 28. Oyama T, Inoue H, Arima M, et al. Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology: magnifying endoscopic classification of the Japan Esophageal Society. *Esophagus* 2017;14:105-112.
 29. Ra J, Paulson EC, Kucharczuk J, et al. Postoperative mortality after esophagectomy for cancer: development of a preoperative risk prediction model. *Ann Surg Oncol* 2008;15:1577-1584.
 30. Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD. Outcomes after transhiatal and transthoracic esophagectomy for cancer. *Ann Thorac Surg* 2008;85:424-429.
 31. Connors RC, Reuben BC, Neumayer LA, Bull DA. Comparing outcomes after transthoracic and transhiatal esophagectomy: a 5-year prospective cohort of 17,395 patients. *J Am Coll Surg* 2007;205:735-740.
 32. Min YW, Lee H, Song BG, et al. Comparison of endoscopic submucosal dissection and surgery for superficial esophageal squamous cell carcinoma: a propensity score-matched analysis. *Gastrointest Endosc* 2018;88:624-633.
 33. Zhang Y, Ding H, Chen T, et al. Outcomes of endoscopic submucosal dissection vs esophagectomy for T1 esophageal squamous cell carcinoma in a real-world cohort. *Clin Gastroenterol Hepatol* 2019;17:73-81.
 34. Shimizu Y, Omori T, Yokoyama A, et al. Endoscopic diagnosis of early squamous neoplasia of the esophagus with iodine staining: high-grade intra-epithelial neoplasia turns pink within a few minutes. *J Gastroenterol Hepatol* 2008;23:546-550.
 35. Ishihara R, Kanzaki H, Iishi H, et al. Pink-color sign in esophageal squamous neoplasia, and speculation regarding the underlying mechanism. *World J Gastroenterol* 2013;19:4300-4308.
 36. Uedo N, Fujishiro M, Goda K, et al. Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region. *Dig Endosc* 2011;23 Suppl 1:58-71.
 37. Gai W, Jin XF, Du R, Li L, Chai TH. Efficacy of narrow-band imaging in detecting early esophageal cancer and risk factors for its occurrence. *Indian J Gastroenterol* 2018;37:79-85.
 38. Goda K, Dobashi A, Yoshimura N, et al. Narrow-band imaging magnifying endoscopy versus lugol chromoendoscopy with pink-color sign assessment in the diagnosis of superficial esophageal squamous neoplasms: a randomised noninferiority trial. *Gastroenterol Res Pract* 2015;2015:639462.
 39. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric

- junction: application to clinical practice. *Ann Cardiothorac Surg* 2017;6:119-130.
40. Puli SR, Reddy JB, Bechtold ML, Antillon D, Ibdah JA, Antillon MR. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. *World J Gastroenterol* 2008;14:1479-1490.
 41. Goda K, Tajiri H, Ikegami M, et al. Magnifying endoscopy with narrow band imaging for predicting the invasion depth of superficial esophageal squamous cell carcinoma. *Dis Esophagus* 2009;22:453-460.
 42. Katada C, Tanabe S, Wada T, et al. Retrospective assessment of the diagnostic accuracy of the depth of invasion by narrow band imaging magnifying endoscopy in patients with superficial esophageal squamous cell carcinoma. *J Gastrointest Cancer* 2019;50:292-297.
 43. Ishihara R, Iishi H, Uedo N, et al. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. *Gastrointest Endosc* 2008;68:1066-1072.
 44. Takahashi H, Arimura Y, Masao H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). *Gastrointest Endosc* 2010;72:255-264.
 45. Teoh AY, Chiu PW, Yu Ngo DK, Wong SK, Lau JY, Ng EK. Outcomes of endoscopic submucosal dissection versus endoscopic mucosal resection in management of superficial squamous esophageal neoplasms outside Japan. *J Clin Gastroenterol* 2010;44:e190-e194.
 46. Urabe Y, Hiyama T, Tanaka S, Yoshihara M, Arihiro K, Chayama K. Advantages of endoscopic submucosal dissection versus endoscopic oblique aspiration mucosectomy for superficial esophageal tumors. *J Gastroenterol Hepatol* 2011;26:275-280.
 47. Yamashita T, Zeniya A, Ishii H, et al. Endoscopic mucosal resection using a cap-fitted panendoscope and endoscopic submucosal dissection as optimal endoscopic procedures for superficial esophageal carcinoma. *Surg Endosc* 2011;25:2541-2546.
 48. Guo HM, Zhang XQ, Chen M, Huang SL, Zou XP. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. *World J Gastroenterol* 2014;20:5540-5547.
 49. Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. *Endoscopy* 2009;41:751-757.
 50. Ono S, Fujishiro M, Niimi K, et al. Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. *Endoscopy* 2009;41:661-665.
 51. Hashimoto S, Kobayashi M, Takeuchi M, Sato Y, Narisawa R, Aoyagi Y. The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. *Gastrointest Endosc* 2011;74:1389-1393.
 52. Hanaoka N, Ishihara R, Takeuchi Y, et al. Intralesional steroid injection to prevent stricture after endoscopic submucosal dissection for esophageal cancer: a controlled prospective study. *Endoscopy* 2012;44:1007-1011.
 53. Takahashi H, Arimura Y, Okahara S, et al. A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection. *BMC Gastroenterol* 2015;15:1.
 54. Kataoka M, Anzai S, Shirasaki T, et al. Efficacy of short period, low dose oral prednisolone for the prevention of stricture after circumferential endoscopic submucosal dissection (ESD) for esophageal cancer. *Endosc Int Open* 2015;3:E113-E117.
 55. Zhou G, Yuan F, Cai J, et al. Efficacy of prednisone for prevention of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. *Thorac Cancer* 2017;8:489-494.
 56. Yamaguchi N, Isomoto H, Nakayama T, et al. Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. *Gastrointest Endosc* 2011;73:1115-1121.
 57. Sato H, Inoue H, Kobayashi Y, et al. Control of severe strictures after circumferential endoscopic submucosal dissection for esophageal carcinoma: oral steroid therapy with balloon dilation or balloon dilation alone. *Gastrointest Endosc* 2013;78:250-257.
 58. Nagami Y, Shiba M, Tominaga K, et al. Locoregional steroid injection prevents stricture formation after endoscopic submucosal dissection for esophageal cancer: a propensity score matching analysis. *Surg Endosc* 2016;30:1441-1449.
 59. Eguchi T, Nakanishi Y, Shimoda T, et al. Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. *Mod Pathol* 2006;19:475-480.
 60. Akutsu Y, Uesato M, Shuto K, et al. The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a ret-

- rospective analysis of 295 patients. *Ann Surg* 2013;257:1032-1038.
61. Choi JY, Park YS, Jung HY, et al. Feasibility of endoscopic resection in superficial esophageal squamous carcinoma. *Gastrointest Endosc* 2011;73:881-889.
 62. Tachibana M, Yoshimura H, Kinugasa S, et al. Clinicopathological features of superficial squamous cell carcinoma of the esophagus. *Am J Surg* 1997;174:49-53.
 63. Endo M, Yoshino K, Kawano T, Nagai K, Inoue H. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. *Dis Esophagus* 2000;13:125-129.
 64. Araki K, Ohno S, Egashira A, Saeki H, Kawaguchi H, Sugimachi K. Pathologic features of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis. *Cancer* 2002;94:570-575.
 65. Bollschweiler E, Baldus SE, Schroder W, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. *Endoscopy* 2006;38:149-156.
 66. Kim DU, Lee JH, Min BH, et al. Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma. *J Gastroenterol Hepatol* 2008;23:619-625.
 67. Moriya H, Ohbu M, Kobayashi N, et al. Lymphatic tumor emboli detected by D2-40 immunostaining can more accurately predict lymph-node metastasis. *World J Surg* 2011;35:2031-2037.
 68. Yamashina T, Ishihara R, Nagai K, et al. Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. *Am J Gastroenterol* 2013;108:544-551.
 69. Oyama T, Tomori A, Hotta K, et al. Endoscopic submucosal dissection of early esophageal cancer. *Clin Gastroenterol Hepatol* 2005;3:S67-S70.
 70. Katada C, Muto M, Momma K, et al. Clinical outcome after endoscopic mucosal resection for esophageal squamous cell carcinoma invading the muscularis mucosae: a multicenter retrospective cohort study. *Endoscopy* 2007;39:779-783.
 71. Park HC, Kim DH, Gong EJ, et al. Ten-year experience of esophageal endoscopic submucosal dissection of superficial esophageal neoplasms in a single center. *Korean J Intern Med* 2016;31:1064-1072.
 72. Song BG, Min YW, Cha RR, et al. Endoscopic submucosal dissection under general anesthesia for superficial esophageal squamous cell carcinoma is associated with better clinical outcomes. *BMC Gastroenterol* 2018;18:80.
 73. Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. *Ann Surg Oncol* 2012;19:2135-2141.
 74. Kawaguchi G, Sasamoto R, Abe E, et al. The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. *Radiat Oncol* 2015; 10:31.
 75. Ikeda A, Hoshi N, Yoshizaki T, et al. Endoscopic submucosal dissection (ESD) with additional therapy for superficial esophageal cancer with submucosal invasion. *Intern Med* 2015;54:2803-2813.
 76. Hamada K, Ishihara R, Yamasaki Y, et al. Efficacy and safety of endoscopic resection followed by chemoradiotherapy for superficial esophageal squamous cell carcinoma: a retrospective study. *Clin Transl Gastroenterol* 2017;8:e110.
 77. Kurokawa Y, Muto M, Minashi K, Boku N, Fukuda H; Gastrointestinal Oncology Study Group of Japan Clinical Oncology G. A phase II trial of combined treatment of endoscopic mucosal resection and chemoradiotherapy for clinical stage I esophageal carcinoma: Japan Clinical Oncology Group Study JCOG0508. *Jpn J Clin Oncol* 2009;39:686-689.
 78. Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma. *Gastroenterology* 2019;157: 382-390.
 79. Ezoe Y, Muto M, Uedo N, et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. *Gastroenterology* 2011; 141:2017-2025.
 80. Kawahara Y, Takenaka R, Okada H, et al. Novel chromoendoscopic method using an acetic acid-indigocarmine mixture for diagnostic accuracy in delineating the margin of early gastric cancers. *Dig Endosc* 2009;21:14-19.
 81. Lee BE, Kim GH, Park DY, et al. Acetic acid-indigo carmine chromoendoscopy for delineating early gastric cancers: its usefulness according to histological type. *BMC Gastroenterol* 2010;10:97.
 82. Tsujii Y, Kato M, Inoue T, et al. Integrated diagnostic strategy for the invasion depth of early gastric cancer by conventional endoscopy and EUS. *Gastrointest Endosc* 2015;82:452-459.
 83. Choi J, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Is endoscopic ultrasonography indispensable in patients with early gastric cancer prior to endoscopic resection? *Surg Endosc* 2010;24:3 177-3185.
 84. Choi J, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Comparison

- of endoscopic ultrasonography and conventional endoscopy for prediction of depth of tumor invasion in early gastric cancer. *Endoscopy* 2010;42:705-713.
85. Yanai H, Noguchi T, Mizumachi S, et al. A blind comparison of the effectiveness of endoscopic ultrasonography and endoscopy in staging early gastric cancer. *Gut* 1999;44:361-365.
 86. Yanai H, Matsumoto Y, Harada T, et al. Endoscopic ultrasonography and endoscopy for staging depth of invasion in early gastric cancer: a pilot study. *Gastrointest Endosc* 1997;46:212-216.
 87. Okada K, Fujisaki J, Kasuga A, et al. Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection. *Surg Endosc* 2011;25:841-848.
 88. Akashi K, Yanai H, Nishikawa J, et al. Ulcerous change decreases the accuracy of endoscopic ultrasonography diagnosis for the invasive depth of early gastric cancer. *Int J Gastrointest Cancer* 2006;37:133-138.
 89. Yoshida S, Tanaka S, Kunihiro K, et al. Diagnostic ability of high-frequency ultrasound probe sonography in staging early gastric cancer, especially for submucosal invasion. *Abdom Imaging* 2005;30:518-523.
 90. Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. *Gastric Cancer* 2000;3:219-225.
 91. Nishizawa T, Yahagi N. Long-term outcomes of using endoscopic submucosal dissection to treat early gastric cancer. *Gut Liver* 2018;12:119-124.
 92. Abdelfatah MM, Barakat M, Lee H, et al. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis. *Gastrointest Endosc* 2018;87:338-347.
 93. Choi KS, Jung HY, Choi KD, et al. EMR versus gastrectomy for intramucosal gastric cancer: comparison of long-term outcomes. *Gastrointest Endosc* 2011;73:942-948.
 94. Choi IJ, Lee JH, Kim YI, et al. Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection. *Gastrointest Endosc* 2015;81:333-341.
 95. Hahn KY, Park CH, Lee YK, et al. Comparative study between endoscopic submucosal dissection and surgery in patients with early gastric cancer. *Surg Endosc* 2018;32:73-86.
 96. Choi JH, Kim ES, Lee YJ, et al. Comparison of quality of life and worry of cancer recurrence between endoscopic and surgical treatment for early gastric cancer. *Gastrointest Endosc* 2015;82:299-307.
 97. Kim JH, Kim SS, Lee JH, et al. Early detection is important to reduce the economic burden of gastric cancer. *J Gastric Cancer* 2018;18:82-89.
 98. Kim YI, Kim YA, Kim CG, et al. Serial intermediate-term quality of life comparison after endoscopic submucosal dissection versus surgery in early gastric cancer patients. *Surg Endosc* 2018;32:2114-2122.
 99. Kim TS, Min BH, Kim KM, Lee JH, Rhee PL, Kim JJ. Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. *Gastric Cancer* 2019;22:363-368.
 100. Lee S, Choi KD, Han M, et al. Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer meeting expanded indication including undifferentiated-type tumors: a criteria-based analysis. *Gastric Cancer* 2018;21:490-499.
 101. Min BH, Kim ER, Kim KM, et al. Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer. *Endoscopy* 2015;47:784-793.
 102. Chang JY, Shim KN, Tae CH, et al. Comparison of clinical outcomes after endoscopic submucosal dissection and surgery in the treatment of early gastric cancer: a single-institute study. *Medicine (Baltimore)* 2017;96:e7210.
 103. Chiu PW, Teoh AY, To KE, et al. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. *Surg Endosc* 2012;26:3584-3591.
 104. Cho JH, Cha SW, Kim HG, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a comparison study to surgery using propensity score-matched analysis. *Surg Endosc* 2016;30:3762-3773.
 105. Feng F, Sun L, Xu G, et al. Is it reasonable to treat early gastric cancer with mucosal infiltration and well differentiation by endoscopic submucosal resection? *J Gastrointest Surg* 2015;19:2111-2119.
 106. Fukunaga S, Nagami Y, Shiba M, et al. Long-term prognosis of expanded-indication differentiated-type early gastric cancer treated with endoscopic submucosal dissection or surgery using propensity score analysis. *Gastrointest Endosc* 2017;85:143-152.
 107. Gong EJ, Kim DH, Ahn JY, et al. Comparison of long-term out-

- comes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. *Gastric Cancer* 2017;20:84-91.
108. Kim YI, Kim YW, Choi IJ, et al. Long-term survival after endoscopic resection versus surgery in early gastric cancers. *Endoscopy* 2015;45:293-301.
 109. Pyo JH, Lee H, Min BH, et al. Long-term outcome of endoscopic resection vs. surgery for early gastric cancer: a non-inferiority-matched cohort study. *Am J Gastroenterol* 2016;111:240-249.
 110. Fujiya K, Takizawa K, Tokunaga M, et al. The value of diagnostic endoscopic submucosal dissection for patients with clinical submucosal invasive early gastric cancer. *Gastric Cancer* 2018;21:124-132.
 111. Lee HD, Chung H, Kim SG, et al. Exploring the possibility of endoscopic submucosal dissection for clinical submucosal invasive early gastric cancers. *Surg Endosc* 2019;33:4008-4015.
 112. Kim DY, Joo JK, Ryu SY, Kim YJ, Kim SK. Factors related to lymph node metastasis and surgical strategy used to treat early gastric carcinoma. *World J Gastroenterol* 2004;10:737-740.
 113. Kim JH, Lee YC, Kim H, et al. Endoscopic resection for undifferentiated early gastric cancer. *Gastrointest Endosc* 2009;69:e1-e9.
 114. Abe S, Oda I, Suzuki H, et al. Short- and long-term outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. *Endoscopy* 2013;45:703-707.
 115. Ahn JY, Park HJ, Park YS, et al. Endoscopic resection for undifferentiated-type early gastric cancer: immediate endoscopic outcomes and long-term survivals. *Dig Dis Sci* 2016;61:1158-1164.
 116. Kim JH, Kim YH, Jung DH, et al. Follow-up outcomes of endoscopic resection for early gastric cancer with undifferentiated histology. *Surg Endosc* 2014;28:2627-2633.
 117. Oda I, Oyama T, Abe S, et al. Preliminary results of multicenter questionnaire study on long-term outcomes of curative endoscopic submucosal dissection for early gastric cancer. *Dig Endosc* 2014;26:214-219.
 118. Park JC, Lee YK, Kim SY, et al. Long-term outcomes of endoscopic submucosal dissection in comparison to surgery in undifferentiated-type intramucosal gastric cancer using propensity score analysis. *Surg Endosc* 2018;32:2046-2057.
 119. Fujishiro M, Chiu PW, Wang HP. Role of antisecretory agents for gastric endoscopic submucosal dissection. *Dig Endosc* 2013;25 Suppl 1:86-93.
 120. Ono H, Yao K, Fujishiro M, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. *Dig Endosc* 2016;28:3-15.
 121. Park CH, Lee SK. Preventing and controlling bleeding in gastric endoscopic submucosal dissection. *Clin Endosc* 2013;46:456-462.
 122. Takizawa K, Oda I, Gotoda T, et al. Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection: an analysis of risk factors. *Endoscopy* 2008;40:179-183.
 123. Kang SH, Lee K, Lee HW, Park GE, Hong YS, Min BH. Delayed perforation occurring after endoscopic submucosal dissection for early gastric cancer. *Clin Endosc* 2015;48:251-255.
 124. Lee H, Cheoi KS, Chung H, et al. Clinical features and predictive factors of coagulation syndrome after endoscopic submucosal dissection for early gastric neoplasm. *Gastric Cancer* 2012;15:83-90.
 125. Uedo N, Takeuchi Y, Yamada T, et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. *Am J Gastroenterol* 2007;102:1610-1616.
 126. Ye BD, Cheon JH, Choi KD, et al. Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. *Aliment Pharmacol Ther* 2006;24:837-843.
 127. Imaeda H, Hosoe N, Suzuki H, et al. Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia. *J Gastroenterol* 2011;46:1267-1272.
 128. Tomita T, Kim Y, Yamasaki T, et al. Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection. *J Gastroenterol Hepatol* 2012;27:1441-1446.
 129. Yang Z, Wu Q, Liu Z, Wu K, Fan D. Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials. *Digestion* 2011;84:315-320.
 130. Arai M, Matsumura T, Okimoto K, et al. Two-week treatment with proton pump inhibitor is sufficient for healing post endoscopic submucosal dissection ulcers. *World J Gastroenterol* 2014;20:16318-16322.

131. Niimi K, Fujishiro M, Goto O, et al. Prospective single-arm trial of two-week rabeprazole treatment for ulcer healing after gastric endoscopic submucosal dissection. *Dig Endosc* 2012; 24:110-116.
132. Lee SH, Lee CK, Chung IK, et al. Optimal duration of proton pump inhibitor in the treatment of endoscopic submucosal dissection-induced ulcers: a retrospective analysis and prospective validation study. *Dig Dis Sci* 2012;57:429-434.
133. Shin WG, Kim SJ, Choi MH, et al. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. *Gastrointest Endosc* 2012;75:739-747.
134. Higuchi K, Takeuchi T, Uedo N, et al. Efficacy and safety of 1-week *Helicobacter pylori* eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, multicenter study. *Gastric Cancer* 2015;18:612-617.
135. Fujiwara S, Morita Y, Toyonaga T, et al. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. *J Gastroenterol* 2011;46:595-602.
136. Jung SW, Kim SY, Choe JW, et al. Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection. *J Gastroenterol Hepatol* 2017;32:778-781.
137. Park JH, Baek EK, Choi CH, et al. Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study. *Surg Endosc* 2014;28:235-241.
138. Nakamura K, Ihara E, Akiho H, et al. Limited effect of rebamipide in addition to proton pump inhibitor (PPI) in the treatment of post-endoscopic submucosal dissection gastric ulcers: a randomized controlled trial comparing PPI plus rebamipide combination therapy with PPI monotherapy. *Gut Liver* 2016;10:917-924.
139. Kawano S, Okada H, Kawahara Y, et al. Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial. *Digestion* 2011;84:46-53.
140. Kim EH, Park SW, Nam E, Lee JG, Park CH. Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis. *Surg Endosc* 2019;33:1271-1283.
141. Oh TH, Jung HY, Choi KD, et al. Degree of healing and healing-associated factors of endoscopic submucosal dissection-induced ulcers after pantoprazole therapy for 4 weeks. *Dig Dis Sci* 2009;54:1494-1499.
142. Park HJ, Kim HS, Kim BR, et al. Half-dose rabeprazole has an equal efficacy to standard-dose rabeprazole on endoscopic submucosal dissection-induced ulcer. *Dig Dis Sci* 2013;58: 1054-1061.
143. Mochizuki S, Uedo N, Oda I, et al. Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial. *Gut* 2015;64:397-405.
144. Ryu HY, Kim JW, Kim HS, et al. Second-look endoscopy is not associated with better clinical outcomes after gastric endoscopic submucosal dissection: a prospective, randomized, clinical trial analyzed on an as-treated basis. *Gastrointest Endosc* 2013;78:285-294.
145. Nishizawa T, Suzuki H, Akimoto T, et al. Effects of preoperative proton pump inhibitor administration on bleeding after gastric endoscopic submucosal dissection: a systematic review and meta-analysis. *United European Gastroenterol J* 2016;4:5-10.
146. Oda I, Suzuki H, Nonaka S, Yoshinaga S. Complications of gastric endoscopic submucosal dissection. *Dig Endosc* 2013;25 Suppl 1:71-78.
147. Jeon SW, Jung MK, Kim SK, et al. Clinical outcomes for perforations during endoscopic submucosal dissection in patients with gastric lesions. *Surg Endosc* 2010;24:911-916.
148. Jeong G, Lee JH, Yu MK, et al. Non-surgical management of microperforation induced by EMR of the stomach. *Dig Liver Dis* 2006;38:605-608.
149. Minami S, Gotoda T, Ono H, Oda I, Hamanaka H. Complete endoscopic closure of gastric perforation induced by endoscopic resection of early gastric cancer using endoclips can prevent surgery (with video). *Gastrointest Endosc* 2006;63: 596-601.
150. Paspatis GA, Dumonceau JM, Barthet M, et al. Diagnosis and management of iatrogenic endoscopic perforations: European Society of Gastrointestinal Endoscopy (ESGE) position statement. *Endoscopy* 2014;46:693-711.
151. Fu K, Ishikawa T, Yamamoto T, Kaji Y. Paracentesis for successful treatment of tension pneumoperitoneum related to endoscopic submucosal dissection. *Endoscopy* 2009;41 Suppl 2:E245.
152. ASGE Technology Committee, Lo SK, Fujii-Lau LL, et al. The use of carbon dioxide in gastrointestinal endoscopy. *Gastro-*

- intest Endosc 2016;83:857-865.
153. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer* 2011;14: 113-123.
 154. Hirasawa T, Gotoda T, Miyata S, et al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. *Gastric Cancer* 2009;12:148-152.
 155. Pyo JH, Shin CM, Lee H, et al. A risk-prediction model based on lymph-node metastasis for incorporation into a treatment algorithm for signet ring cell-type intramucosal gastric cancer. *Ann Surg* 2016;264:1038-1043.
 156. Hatta W, Gotoda T, Oyama T, et al. A scoring system to stratify curability after endoscopic submucosal dissection for early gastric cancer: "eCura system". *Am J Gastroenterol* 2017;112: 874-881.
 157. Kawata N, Kakushima N, Takizawa K, et al. Risk factors for lymph node metastasis and long-term outcomes of patients with early gastric cancer after non-curative endoscopic submucosal dissection. *Surg Endosc* 2017;31:1607-1616.
 158. Hatta W, Gotoda T, Oyama T, et al. Is radical surgery necessary in all patients who do not meet the curative criteria for endoscopic submucosal dissection in early gastric cancer? A multi-center retrospective study in Japan. *J Gastroenterol* 2017;52:175-184.
 159. Suzuki H, Oda I, Abe S, et al. Clinical outcomes of early gastric cancer patients after noncurative endoscopic submucosal dissection in a large consecutive patient series. *Gastric Cancer* 2017;20:679-689.
 160. Pyo JH, Lee H, Min YW, et al. Feasibility of endoscopic resection in early gastric cancer with lymphovascular invasion. *Ann Surg Oncol* 2019;26:449-455.
 161. Choi JY, Jeon SW, Cho KB, et al. Non-curative endoscopic resection does not always lead to grave outcomes in submucosal invasive early gastric cancer. *Surg Endosc* 2015;29:1842-1849.
 162. Toyokawa T, Ohira M, Tanaka H, et al. Optimal management for patients not meeting the inclusion criteria after endoscopic submucosal dissection for gastric cancer. *Surg Endosc* 2016;30:2404-2414.
 163. Toya Y, Endo M, Nakamura S, et al. Clinical outcomes of non-curative endoscopic submucosal dissection with negative resected margins for gastric cancer. *Gastrointest Endosc* 2017; 85:1218-1224.
 164. Hatta W, Gotoda T, Oyama T, et al. Is the eCura system useful for selecting patients who require radical surgery after noncurative endoscopic submucosal dissection for early gastric cancer? A comparative study. *Gastric Cancer* 2018;21:481-489.
 165. Eom BW, Kim YI, Kim KH, et al. Survival benefit of additional surgery after noncurative endoscopic resection in patients with early gastric cancer. *Gastrointest Endosc* 2017;85:155-163.
 166. Kim ER, Lee H, Min BH, et al. Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. *Br J Surg* 2015;102:1394-1401.
 167. Suzuki S, Gotoda T, Hatta W, et al. Survival benefit of additional surgery after non-curative endoscopic submucosal dissection for early gastric cancer: a propensity score matching analysis. *Ann Surg Oncol* 2017;24:3353-3360.
 168. Jung DH, Lee YC, Kim JH, et al. Additive treatment improves survival in elderly patients after non-curative endoscopic resection for early gastric cancer. *Surg Endosc* 2017;31:1376-1382.
 169. Kusano C, Iwasaki M, Kaltenbach T, Conlin A, Oda I, Gotoda T. Should elderly patients undergo additional surgery after non-curative endoscopic resection for early gastric cancer? Long-term comparative outcomes. *Am J Gastroenterol* 2011; 106:1064-1069.
 170. Pyo JH, Lee H, Min BH, et al. Comparison of long-term outcomes after non-curative endoscopic resection in older patients with early gastric cancer. *Ann Surg Oncol* 2017;24: 2624-2631.
 171. Sekiguchi M, Suzuki H, Oda I, et al. Risk of recurrent gastric cancer after endoscopic resection with a positive lateral margin. *Endoscopy* 2014;46:273-278.
 172. Han JP, Hong SJ, Kim HK, et al. Risk stratification and management of non-curative resection after endoscopic submucosal dissection for early gastric cancer. *Surg Endosc* 2016;30: 184-189.
 173. Jeon MY, Park JC, Hahn KY, Shin SK, Lee SK, Lee YC. Long-term outcomes after noncurative endoscopic resection of early gastric cancer: the optimal time for additional endoscopic treatment. *Gastrointest Endosc* 2018;87:1003-1013.
 174. Oh S, Kim SG, Choi JM, et al. Ablation of residual gastric tumor by argon plasma coagulation after endoscopic resection. *Surg Endosc* 2017;31:1093-1100.
 175. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet* 2008;372: 392-397.
 176. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis

- and treatment of *Helicobacter pylori* infection in Korea, 2013 revised edition. *J Gastroenterol Hepatol* 2014;29:1371-1386.
177. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of *Helicobacter pylori* infection-the Maastricht V/Florence Consensus Report. *Gut* 2017;66:6-30.
178. Chey WD, Leontiadis GI, Howden CW, Moss SE. ACG clinical guideline: treatment of *Helicobacter pylori* infection. *Am J Gastroenterol* 2017;112:212-239.
179. Mahachai V, Vilaichone RK, Pittayanon R, et al. *Helicobacter pylori* management in ASEAN: The Bangkok consensus report. *J Gastroenterol Hepatol* 2018;33:37-56.
180. Liu WZ, Xie Y, Lu H, et al. Fifth Chinese national consensus report on the management of *Helicobacter pylori* infection. *Helicobacter* 2018;23:e12475.
181. Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of *Helicobacter pylori* eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. *Helicobacter* 2014;19:243-248.
182. Bang CS, Baik GH, Shin IS, et al. *Helicobacter pylori* eradication for prevention of metachronous recurrence after endoscopic resection of early gastric cancer. *J Korean Med Sci* 2015;30:749-756.
183. Lee YC, Chiang TH, Chou CK, et al. Association between *Helicobacter pylori* eradication and gastric cancer incidence: a systematic review and meta-analysis. *Gastroenterology* 2016;150:1113-1124.
184. Sugano K. Effect of *Helicobacter pylori* eradication on the incidence of gastric cancer: a systematic review and meta-analysis. *Gastric Cancer* 2019;22:435-445.
185. Choi IJ, Kook MC, Kim YI, et al. *Helicobacter pylori* therapy for the prevention of metachronous gastric cancer. *N Engl J Med* 2018;378:1085-1095.
186. Choi JM, Kim SG, Choi J, et al. Effects of *Helicobacter pylori* eradication for metachronous gastric cancer prevention: a randomized controlled trial. *Gastrointest Endosc* 2018;88:475-485.
187. Lee JH, Kim JG, Jung HK, et al. Synopsis on clinical practice guideline of gastric cancer in Korea: an evidence-based approach. *Korean J Gastroenterol* 2014;63:66-81.
188. Kim SG, Park CM, Lee NR, et al. Long-term clinical outcomes of endoscopic submucosal dissection in patients with early gastric cancer: a prospective multicenter cohort study. *Gut Liver* 2018;12:402-410.
189. Kato M, Nishida T, Yamamoto K, et al. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. *Gut* 2013;62:1425-1432.
190. Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection. *Endoscopy* 2005;37:990-993.
191. Abe S, Oda I, Suzuki H, et al. Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. *Endoscopy* 2015;47:1113-1118.
192. Hahn KY, Park JC, Kim EH, et al. Incidence and impact of scheduled endoscopic surveillance on recurrence after curative endoscopic resection for early gastric cancer. *Gastrointest Endosc* 2016;84:628-638.
193. Yang HJ, Kim SG, Lim JH, et al. Novel risk stratification for metachronous recurrence after curative endoscopic submucosal dissection for early gastric cancer. *Gastrointest Endosc* 2018;87:419-428.
194. Lee S, Choi KD, Hong SM, et al. Pattern of extragastric recurrence and the role of abdominal computed tomography in surveillance after endoscopic resection of early gastric cancer: Korean experiences. *Gastric Cancer* 2017;20:843-852.
195. Choi KS, Kim SH, Kim SG, Han JK. Early gastric cancers: is surveillance necessary after curative endoscopic submucosal resection for cancers that meet the expanded criteria? *Radiology* 2016;281:444-453.
196. Park CH, Kim EH, Chung H, et al. Role of computed tomography scan for the primary surveillance of mucosal gastric cancer after complete resection by endoscopic submucosal dissection. *Surg Endosc* 2014;28:1307-1313.
197. Jung SA, Yang SK, Kang GH, et al. Risk factors of lymph node metastasis in submucosally invasive colorectal carcinoma: with special reference to the depth of invasion. *Korean J Gastrointest Endosc* 2001;22:411-418.
198. Choi PW, Yu CS, Jang SJ, Jung SH, Kim HC, Kim JC. Risk factors for lymph node metastasis in submucosal invasive colorectal cancer. *World J Surg* 2008;32:2089-2094.
199. Sung HY, Kang WK, Kim SW, et al. Risk factors for lymph node metastasis in patients with submucosal invasive colorectal carcinoma. *Journal of the Korean Surgical Society* 2010;78:207-212.
200. Lee SH, Kang HJ, Ahn BK, et al. Clinicopathologic factors for prediction of lymph node metastasis in submucosally invasive colorectal carcinoma. *J Korean Surg Soc* 2011;80:111-118.
201. Ueno H, Hase K, Hashiguchi Y, et al. Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a

- multi-institution pathology review. *J Gastroenterol* 2014;49:1314-1323.
202. Han J, Hur H, Min BS, Lee KY, Kim NK. Predictive factors for lymph node metastasis in submucosal invasive colorectal carcinoma: a new proposal of depth of invasion for radical surgery. *World J Surg* 2018;42:2635-2641.
 203. Kim B, Kim EH, Park SJ, et al. The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer: a retrospective study of 428 patients. *Medicine (Baltimore)* 2016;95:e4373.
 204. Al-Sukhni E, Attwood K, Gabriel EM, LeVeae CM, Kanehira K, Nurkin SJ. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: a retrospective cohort study. *Int J Surg* 2017;37:42-49.
 205. Ha RK, Han KS, Sohn DK, et al. Histopathologic risk factors for lymph node metastasis in patients with T1 colorectal cancer. *Ann Surg Treat Res* 2017;93:266-271.
 206. Beaton C, Twine CP, Williams GL, Radcliffe AG. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. *Colorectal Dis* 2013;15:788-797.
 207. Mou S, Soetikno R, Shimoda T, Rouse R, Kaltenbach T. Pathologic predictive factors for lymph node metastasis in submucosal invasive (T1) colorectal cancer: a systematic review and meta-analysis. *Surg Endosc* 2013;27:2692-2703.
 208. Choi JY, Jung SA, Shim KN, et al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma. *J Korean Med Sci* 2015;30:398-406.
 209. Tanaka S, Haruma K, Teixeira CR, et al. Endoscopic treatment of submucosal invasive colorectal carcinoma with special reference to risk factors for lymph node metastasis. *J Gastroenterol* 1995;30:710-717.
 210. Kikuchi R, Takano M, Takagi K, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. *Dis Colon Rectum* 1995;38:1286-1295.
 211. Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. *Endoscopy* 1993;25:455-461.
 212. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. *Gastroenterology* 1985;89:328-336.
 213. Park YJ, Kim WH, Paeng SS, Park JG. Histoclinical analysis of early colorectal cancer. *World J Surg* 2000;24:1029-1035.
 214. Choi DH, Sohn DK, Chang HJ, Lim SB, Choi HS, Jeong SY. Indications for subsequent surgery after endoscopic resection of submucosally invasive colorectal carcinomas: a prospective cohort study. *Dis Colon Rectum* 2009;52:438-445.
 215. Lim KH, Jung SW, Jeong ID, et al. Risk factors for lymph node metastasis after endoscopic resection for early colorectal cancer. *Intest Res* 2008;6:103-109.
 216. Lee SH, Cho HD, Park DI, et al. Pathological predictors for defining a therapeutic strategy for early colon cancer after endoscopic resection: multicenter retrospective analysis from surgically resected specimens. *Hepatogastroenterology* 2014;61:642-646.
 217. Nakadoi K, Oka S, Tanaka S, et al. Condition of muscularis mucosae is a risk factor for lymph node metastasis in T1 colorectal carcinoma. *Surg Endosc* 2014;28:1269-1276.
 218. Nishida T, Egashira Y, Akutagawa H, et al. Predictors of lymph node metastasis in T1 colorectal carcinoma: an immunophenotypic analysis of 265 patients. *Dis Colon Rectum* 2014;57:905-915.
 219. Kawachi H, Eishi Y, Ueno H, et al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study. *Modern Pathology* 2015;28:872-879.
 220. Barresi V, Reggiani Bonetti L, Vitarelli E, Di Gregorio C, Ponz de Leon M, Barresi G. Immunohistochemical assessment of lymphovascular invasion in stage I colorectal carcinoma: prognostic relevance and correlation with nodal micrometastases. *Am J Surg Pathol* 2012;36:66-72.
 221. Wada H, Shiozawa M, Katayama K, et al. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer. *J Gastroenterol* 2015;50:727-734.
 222. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. *Histopathology* 2002;40:127-132.
 223. Cappellesso R, Luchini C, Veronese N, et al. Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. *Human Pathology* 2017;65:62-70.
 224. Masaki T, Matsuoka H, Sugiyama M, Abe N, Sakamoto A, Atomi Y. Actual number of tumor budding as a new tool for the individualization of treatment of T1 colorectal carcinomas. *J Gastroenterol Hepatol* 2006;21:1115-1121.
 225. Yim K, Won DD, Lee IK, Oh ST, Jung ES, Lee SH. Novel predictors for lymph node metastasis in submucosal invasive colorectal carcinoma. *World J Gastroenterol* 2017;23:5936-

- 5944.
226. Gangireddy VGR, Coleman T, Kanneganti P, et al. Polypectomy versus surgery in early colon cancer: size and location of colon cancer affect long-term survival. *Int J Colorectal Dis* 2018;33:1349-1357.
227. Mounzer R, Das A, Yen RD, et al. Endoscopic and surgical treatment of malignant colorectal polyps: a population-based comparative study. *Gastrointest Endosc* 2015;81:733-740.
228. Kogler P, Kafka-Ritsch R, Öfner D, et al. Is limited surgery justified in the treatment of T1 colorectal cancer? *Surg Endosc* 2013;27:817-825.
229. Belderbos TD, van Erning FN, de Hingh IH, van Oijen MG, Lemmens VE, Siersema PD. Long-term recurrence-free survival after standard endoscopic resection versus surgical resection of submucosal invasive colorectal cancer: a population-based study. *Clin Gastroenterol Hepatol* 2017;15:403-411.
230. Kim JB, Lee HS, Lee HJ, et al. Long-term outcomes of endoscopic versus surgical resection of superficial submucosal colorectal cancer. *Dig Dis Sci* 2015;60:2785-2792.
231. Heo J, Jeon SW, Jung MK, Kim SK, Kim J, Kim S. Endoscopic resection as the first-line treatment for early colorectal cancer: comparison with surgery. *Surg Endosc* 2014;28:3435-3442.
232. Yoda Y, Ikematsu H, Matsuda T, et al. A large-scale multicenter study of long-term outcomes after endoscopic resection for submucosal invasive colorectal cancer. *Endoscopy* 2013;45:718-724.
233. Yoshii S, Nojima M, Noshio K, et al. Factors associated with risk for colorectal cancer recurrence after endoscopic resection of T1 tumors. *Clin Gastroenterol Hepatol* 2014;12:292-302.
234. Asayama N, Oka S, Tanaka S, et al. Long-term outcomes after treatment for T1 colorectal carcinoma. *Int J Colorectal Dis* 2016;31:571-578.
235. Tamaru Y, Oka S, Tanaka S, et al. Long-term outcomes after treatment for T1 colorectal carcinoma: a multicenter retrospective cohort study of Hiroshima GI Endoscopy Research Group. *J Gastroenterol* 2017;52:1169-1179.
236. Kudo S, Tamura S, Nakajima T, Yamano H, Kusaka H, Watanabe H. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. *Gastrointest Endosc* 1996;44:8-14.
237. Hurlstone DP, Cross SS, Adam I, et al. Endoscopic morphological anticipation of submucosal invasion in flat and depressed colorectal lesions: clinical implications and subtype analysis of the kudo type V pit pattern using high-magnification-chromoscopic colonoscopy. *Colorectal Dis* 2004;6:369-375.
238. Ohta A, Tominaga K, Sakai Y. Efficacy of magnifying colonoscopy for the diagnosis of colorectal neoplasia: comparison with histopathological findings. *Dig Endosc* 2004;16:308-314.
239. Tanaka S, Haruma K, Nagata S, Oka S, Chayama K. Diagnosis of invasion depth in early colorectal carcinoma by pit pattern analysis with magnifying endoscopy. *Dig Endosc* 2001;13:S2-S5.
240. Matsuda T, Fujii T, Saito Y, et al. Efficacy of the invasive/non-invasive pattern by magnifying chromoendoscopy to estimate the depth of invasion of early colorectal neoplasms. *Am J Gastroenterol* 2008;103:2700-2706.
241. Zhang QW, Teng LM, Zhang XT, et al. Narrow-band imaging in the diagnosis of deep submucosal colorectal cancers: a systematic review and meta-analysis. *Endoscopy* 2017;49:564-580.
242. Hirata M, Tanaka S, Oka S, et al. Evaluation of microvessels in colorectal tumors by narrow band imaging magnification. *Gastrointest Endosc* 2007;66:945-952.
243. Wada Y, Kudo SE, Kashida H, et al. Diagnosis of colorectal lesions with the magnifying narrow-band imaging system. *Gastrointest Endosc* 2009;70:522-531.
244. Yoo HY, Lee MS, Ko BM, et al. Correlation of narrow band imaging with magnifying colonoscopy and histology in colorectal tumors. *Clin Endosc* 2011;44:44-50.
245. Ikematsu H, Matsuda T, Emura F, et al. Efficacy of capillary pattern type IIIA/IIIB by magnifying narrow band imaging for estimating depth of invasion of early colorectal neoplasms. *BMC Gastroenterol* 2010;10:33.
246. Oba S, Tanaka S, Oka S, et al. Characterization of colorectal tumors using narrow-band imaging magnification: combined diagnosis with both pit pattern and microvessel features. *Scand J Gastroenterol* 2010;45:1084-1092.
247. Sumimoto K, Tanaka S, Shigita K, et al. Clinical impact and characteristics of the narrow-band imaging magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. *Gastrointest Endosc* 2017;85:816-821.
248. Iwatate M, Sano Y, Tanaka S, et al. Validation study for development of the Japan NBI Expert Team classification of colorectal lesions. *Dig Endosc* 2018;30:642-651.
249. Li X, Chen H, Gao Y, Chen X, Ge Z. Prediction of histology and invasive depth of colorectal neoplasia based on morphology of surface depression using magnifying chromocolonoscopy. *Int J Colorectal Dis* 2010;25:79-85.
250. Hisabe T, Tsuda S, Hoashi T, et al. Validity of conventional en-

- doscopy using “non-extension sign” for optical diagnosis of colorectal deep submucosal invasive cancer. *Endosc Int Open* 2018;6:E156-E164.
251. Uno Y, Munakata A. The non-lifting sign of invasive colon cancer. *Gastrointest Endosc* 1994;40:485-489.
 252. Kobayashi N, Saito Y, Sano Y, et al. Determining the treatment strategy for colorectal neoplastic lesions: endoscopic assessment or the non-lifting sign for diagnosing invasion depth? *Endoscopy* 2007;39:701-705.
 253. Sakamoto T, Nakajima T, Matsuda T, et al. Comparison of the diagnostic performance between magnifying chromoendoscopy and magnifying narrow-band imaging for superficial colorectal neoplasms: an online survey. *Gastrointest Endosc* 2018;87:1318-1323.
 254. De Ceglie A, Hassan C, Mangiavillano B, et al. Endoscopic mucosal resection and endoscopic submucosal dissection for colorectal lesions: a systematic review. *Crit Rev Oncol Hematol* 2016;104:138-155.
 255. Belderbos TD, Leenders M, Moons LM, Siersema PD. Local recurrence after endoscopic mucosal resection of nonpedunculated colorectal lesions: systematic review and meta-analysis. *Endoscopy* 2014;46:388-402.
 256. Fuccio L, Repici A, Hassan C, et al. Why attempt en bloc resection of non-pedunculated colorectal adenomas? A systematic review of the prevalence of superficial submucosal invasive cancer after endoscopic submucosal dissection. *Gut* 2018;67:1464-1474.
 257. Fujiya M, Tanaka K, Dokoshi T, et al. Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta-analysis of studies comparing EMR and endoscopic submucosal dissection. *Gastrointest Endosc* 2015;81:583-595.
 258. Arezzo A, Passera R, Marchese N, Galloro G, Manta R, Cirocchi R. Systematic review and meta-analysis of endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal lesions. *United European Gastroenterol J* 2016;4: 18-29.
 259. Liggi M, Cadoni S, Gallittu P. Endoscopic submucosal dissection, endoscopic mucosal resection and hybrid techniques for large nonpedunculated colorectal tumors: a meta analysis and systematic review. *J Interv Gastroenterol* 2014;4:117-125.
 260. Sato T, Fukuzawa M, Gotoda T, Moriyasu F. Comparison of clinical outcomes between colorectal EMR and ESD. *J Tokyo Med Univ* 2016;74:154-162.
 261. Repici A, Hassan C, De Paula Pessoa D, et al. Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review. *Endoscopy* 2012;44:137-150.
 262. Shiga H, Endo K, Kuroha M, et al. Endoscopic submucosal dissection for colorectal neoplasia during the clinical learning curve. *Surg Endosc* 2014;28:2120-2128.
 263. Sakamoto T, Saito Y, Fukunaga S, Nakajima T, Matsuda T. Learning curve associated with colorectal endoscopic submucosal dissection for endoscopists experienced in gastric endoscopic submucosal dissection. *Dis Colon Rectum* 2011; 54:1307-1312.
 264. Bhurwal A, Bartel MJ, Heckman MG, et al. Endoscopic mucosal resection: learning curve for large nonpolypoid colorectal neoplasia. *Gastrointest Endosc* 2016;84:959-968.
 265. Probst A, Golger D, Anthuber M, Märkl B, Messmann H. Endoscopic submucosal dissection in large sessile lesions of the rectosigmoid: learning curve in a European center. *Endoscopy* 2012;44:660-667.
 266. Jeon HH, Lee HS, Youn YH, Park JJ, Park H. Learning curve analysis of colorectal endoscopic submucosal dissection (ESD) for laterally spreading tumors by endoscopists experienced in gastric ESD. *Surg Endosc* 2016;30:2422-2430.

See “Clinical practice guideline for endoscopic resection of early gastrointestinal cancer” on page 127-157.

Supplementary Material 1. PICO for Each Statement

1. Description of PICOs for Superficial Esophageal Squamous Cell Carcinoma

Statement E1: We recommend endoscopic resection for SESCC without distant or lymph node metastasis, excluding those with obvious submucosal invasion. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. What are the indications for endoscopic resection of superficial esophageal squamous cell carcinoma?

Patient: Patients who undergo either endoscopic resection or esophagectomy for superficial esophageal squamous cell carcinoma without lymph node metastasis
Intervention: Endoscopic resection
Comparator: Esophagectomy
Outcome: Survival rate
Study design: Randomized controlled trial (RCT) or non-RCT

Statement E2: We recommend Lugol chromoendoscopy and/or image-enhanced endoscopy to define the extent of lesion before endoscopic treatment of SESCC. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Does chromoendoscopy or image-enhanced endoscopy before endoscopic resection of superficial esophageal squamous cell carcinoma help the evaluation of the lateral margin of the lesion?

Patient: Patients who were diagnosed with superficial esophageal squamous cell carcinoma
Intervention: Chromoendoscopy, image-enhanced endoscopy
Comparator: No chromoendoscopy or image-enhanced endoscopy after diagnosis of superficial esophageal squamous cell carcinoma
Outcome: Lateral margin
Study design: RCT or non-RCT

Statement E3: We recommend endoscopic ultrasound to define the stage of SESCC before endoscopic treatment. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Does endoscopic ultrasound (EUS) before endoscopic resection of superficial esophageal squamous cell carcinoma help to stage the disease?

Patient: Patients who were diagnosed with superficial esophageal squamous cell carcinoma
Intervention: EUS
Comparator: No EUS after diagnosis of superficial esophageal squamous cell carcinoma
Outcome: Depth of invasion, lymph node metastasis
Study design: RCT or non-RCT

Statement E4: We suggest magnifying endoscopy with narrow band imaging for SESCC to assess the depth of invasion before endoscopic treatment. (Grade of recommendation: weak, Level of evidence: low)

Q1. Does magnifying endoscopy with narrow band imaging (MENBI) before endoscopic resection of superficial esophageal squamous cell carcinoma help the evaluation of the depth of invasion?

Patient: Patients who were diagnosed with superficial esophageal squamous cell carcinoma
Intervention: MENBI
Comparator: No MENBI after diagnosis of superficial esophageal squamous cell carcinoma
Outcome: Depth of invasion
Study design: RCT or non-RCT

Statement E5: We recommend endoscopic submucosal dissection rather than endoscopic mucosal resection for en bloc and curative resection of SESCC confined to the mucosa. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Is ESD more effective than EMR in patients with superficial esophageal squamous cell carcinoma in terms of en bloc resection, R0 resection and curative resection?

Patient: Patients who undergo endoscopic resection for superficial esophageal squamous cell carcinoma
Intervention: Endoscopic submucosal dissection
Comparator: Endoscopic mucosal resection
Outcome: en bloc resection, R0 resection, curative resection
Study design: RCT or non-RCT

Statement E6: We recommend oral steroid or local steroid injection therapy for patients who develop mucosal defects in >75% of the esophageal circumference after endoscopic submucosal dissection to prevent esophageal stricture. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Is steroid administration needed after endoscopic resection in patients with superficial esophageal squamous cell carcinoma to decrease the risk of stenosis?

Patient: Patients who undergo endoscopic resection for superficial esophageal squamous cell carcinoma
Intervention: Steroid administration after endoscopic resection (oral administration or local injection)
Comparator: No steroid administration after endoscopic resection
Outcome: Stenosis rate, number of endoscopic dilatation, adverse event
Study design: RCT or non-RCT

Statement E7: No additional treatment is recommended after en bloc complete resection of SESCC invading no more than the lamina propria with no lymphovascular invasion because of a very low risk of lymph node metastasis. (Grade of recommendation: strong, Level of evidence: moderate) As the risk of lymph node metastasis of a tumor invading into the muscularis mucosa without lymphovascular invasion is low, a close follow-up after en bloc complete endoscopic resection can be considered without additional treatment. (Grade of recommendation: weak, Level of evidence: low) In case of a tumor with submucosal invasion, lymphovascular invasion, and/or positive vertical resection margin, additional treatment is recommended. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Is there a difference between observation without surgery and rescue surgery in terms of recurrence and survival in patients who achieve R0 resection by endoscopic resection for mucosal esophageal squamous cell carcinoma without lymphovascular invasion?

Patient: Patients who achieve R0 resection by endoscopic resection for mucosal esophageal squamous cell carcinoma without lymphovascular invasion
Intervention: Observation
Comparator: Rescue (additional) surgery
Outcome: Recurrence and survival rates
Study design: RCT or non-RCT

2. Description of PICO for Early Gastric Cancer

Statement G1: We recommend chromoendoscopy/image-enhanced endoscopy to determine the extent of lesion before endoscopic treatment of early gastric cancer (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Does chromoendoscopy or image-enhanced endoscopy before endoscopic resection of early gastric cancer help the evaluation of the lateral margin of the lesion?

Patient: Patients who were diagnosed with early gastric cancer

Intervention: Chromoendoscopy, image-enhanced endoscopy

Comparator: No chromoendoscopy or image-enhanced endoscopy after diagnosis of early gastric cancer

Outcome: Lateral margin

Study design: RCT or non-RCT

Statement G2: Endoscopic ultrasonography before endoscopic resection of early gastric cancer may be helpful in determining the depth of invasion in some patients with early gastric cancer. (Grade of recommendation: weak, Level of evidence: moderate)

Q1. Does EUS before endoscopic resection of early gastric cancer help the evaluation of the depth of invasion?

Patient: Patients who were diagnosed with early gastric cancer

Intervention: EUS

Comparator: No EUS after diagnosis of early gastric cancer

Outcome: Depth of invasion

Study design: RCT or non-RCT

Statement G3: We recommend endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma meeting endoscopically estimated tumor size ≤ 2 cm and endoscopically suspected mucosal cancer without ulcer. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Can we recommend endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma meeting endoscopically estimated tumor size ≤ 2 cm and endoscopically suspected mucosal cancer without ulcer?

Patient: Patients with early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma meeting endoscopically estimated tumor size ≤ 2 cm and endoscopically suspected mucosal cancer without ulcer

Intervention: Endoscopic resection

Comparator: Gastrectomy with lymph node dissection

Outcome: Survival rate

Study design: RCT or non-RCT

Statement G4: We suggest endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma with the following endoscopic findings: 1) mucosal cancer > 2 cm without ulcer, or 2) mucosal cancer ≤ 3 cm with ulcer. (Grade of recommendation: weak, Level of evidence: moderate)

Q1. Can we suggest endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma with the following endoscopic findings: 1) mucosal cancer > 2 cm without ulcer, or 2) mucosal cancer ≤ 3 cm with ulcer?

Patient: Patients with early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma with the following endoscopic findings: 1) mucosal cancer > 2 cm without ulcer, or 2) mucosal cancer ≤ 3 cm with ulcer

Intervention: Endoscopic resection

Comparator: Gastrectomy with lymph node dissection

Outcome: Survival rate

Study design: RCT or non-RCT

Statement G5: We suggest endoscopic resection for poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, or signet ring cell carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤ 2 cm, endoscopically mucosal cancer, and no ulcer in the tumor (Grade of recommendation: weak, Level of evidence: low)

Q1. Can we suggest endoscopic resection for poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, or signet ring cell carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤ 2 cm, endoscopically mucosal cancer, and no ulcer in the tumor?

Patient: Patients with early gastric cancer of poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, or signet ring cell carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤ 2 cm, endoscopically mucosal cancer, and no ulcer in the tumor

Intervention: Endoscopic resection

Comparator: Gastrectomy with lymph node dissection

Outcome: Survival rate

Study design: RCT or non-RCT

Statement G6: We recommend prophylactic hemostasis of visible vessels on the post-resection ulcer caused by endoscopic resection of early gastric cancer to lower the risk of delayed bleeding (Grade of recommendation: strong, Level of evidence: low)

Q1. Can prophylactic hemostasis of visible vessels on the post-resection ulcer caused by endoscopic resection of early gastric cancer reduce the risk of delayed bleeding?

Patient: Patients who underwent endoscopic resection for early gastric cancer

Intervention: Prophylactic hemostasis of visible vessels on the post-resection ulcer

Comparator: No prophylactic hemostasis

Outcome: Delayed bleeding

Study design: RCT or non-RCT

Statement G7: We recommend proton pump inhibitors to decrease the risk of symptoms and complications associated with iatrogenic ulcers caused by endoscopic resection of early gastric cancer. (Grade of recommendation: strong, Level of evidence: high)

Q1. Can proton pump inhibitors decrease the risk of symptoms and complications associated with iatrogenic ulcers caused by endoscopic resection of early gastric cancer?

Patient: Patients who underwent endoscopic resection for early gastric cancer

Intervention: Use of proton pump inhibitors

Comparator: No use of proton pump inhibitors

Outcome: Symptoms and complications associated with iatrogenic ulcers

Study design: RCT or non-RCT

Statement G8: We recommend endoscopic closure as the first treatment option for perforation that occurred during endoscopic resection of early gastric cancer. (Grade of recommendation: strong, Level of evidence: low)

Q1. What is the first treatment option for perforation that occurred during endoscopic resection of early gastric cancer?

Patient: Patients with perforation that occurred during endoscopic resection

Intervention: Endoscopic closure

Comparator: Surgery or conservative management

Outcome: Closure rate

Study design: RCT or non-RCT

Statement G9: We recommend surgical gastrectomy if histopathological evaluation after endoscopic resection of early gastric cancer meets the criteria for non-curative resection. An exception applies if cancer invasion is observed at the horizontal resection margin only. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Is there a difference between observation without surgery and rescue surgery in terms of recurrence and survival in patients with early gastric cancer meeting the criteria for non-curative resection (an exception applies if cancer invasion is observed at the horizontal resection margin only)?

Patient: Patients with early gastric cancer meeting the criteria for non-curative resection (an exception applies if cancer invasion is observed at the horizontal resection margin only)

Intervention: Rescue surgery

Comparator: Observation without surgery

Outcome: Recurrence and survival

Study design: RCT or non-RCT

Statement G10: We recommend additional endoscopic management rather than surgical gastrectomy if histopathological evaluation of endoscopically resected early gastric cancer specimen shows positive involvement at the horizontal resection margin without any other findings compatible with non-curative resection. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Is there a difference between additional endoscopic therapy without surgery and rescue surgery in terms of recurrence and survival in patients with early gastric cancer with positive involvement at the horizontal resection margin without any other findings compatible with non-curative resection?

Patient: Patients with early gastric cancer with positive involvement at the horizontal resection margin without any other findings compatible with non-curative resection

Intervention: Additional endoscopic therapy

Comparator: Rescue surgery

Outcome: Recurrence and survival

Study design: RCT or non-RCT

Statement G11: We recommend *Helicobacter pylori* (*H. pylori*) eradication treatment after endoscopic resection of early gastric cancer in *H. pylori*-infected patients. (Grade of recommendation: strong, Level of evidence: high)

Q1. Can *Helicobacter pylori* eradication treatment after endoscopic resection of early gastric cancer reduce the metachronous gastric cancer in *H. pylori*-infected patients?

Patient: *H. pylori*-infected patients after endoscopic resection of early gastric cancer

Intervention: *Helicobacter pylori* eradication treatment

Comparator: No eradication

Outcome: Incidence of the metachronous gastric cancer

Study design: RCT or non-RCT

Statement G12: We recommend regular surveillance endoscopy every 6–12 months for patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria for early detection of metachronous gastric cancer. (Grade of recommendation: strong, Level of evidence: low)

Q1. Does regular surveillance endoscopy every 6–12 months help the early detection of metachronous gastric cancer in patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria?

Patient: Patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria
Intervention: Surveillance endoscopy every 6–12 months
Comparator: No surveillance endoscopy
Outcome: Early detection of metachronous gastric cancer
Study design: RCT or non-RCT

Statement G13: We suggest regular abdominopelvic computed tomography scan of 6- to 12-month interval for detection of extra-gastric recurrence after curative endoscopic resection of early gastric cancer based on absolute and expanded criteria. (Grade of recommendation: weak, Level of evidence: low)

Q1. Does regular abdominopelvic computed tomography scan every 6–12 months help the detection of extra-gastric recurrence in patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria?

Patient: Patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria
Intervention: Abdominopelvic computed tomography scan every 6–12 months
Comparator: No surveillance computed tomography scan
Outcome: Detection of extra-gastric recurrence
Study design: RCT or non-RCT

3. Description of PICO for Early Colorectal Cancer

Statement C1: Poor histologic types (poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma), deep submucosal invasion, lymphovascular invasion, and intermediate-to-high-grade tumor budding at the site of deepest invasion are risk factors of lymph node metastasis in early colorectal cancer. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Does intramucosal colorectal cancer have the risk of lymph node metastasis?

Patient: Patients who were diagnosed with intramucosal colorectal cancer
Intervention: Not applicable
Comparator: Not applicable
Outcome: Incidence of lymph node metastasis
Study design: RCT or non-RCT

Q2. Is the risk of lymph node metastasis higher in the deep submucosal invasive colorectal cancer than in the superficial submucosal invasive colorectal cancer?

Patient: Patients who were diagnosed with submucosal colorectal cancer
Intervention: Patients who were diagnosed with deep submucosal colorectal cancer
Comparator: Patients who were diagnosed with superficial submucosal colorectal cancer
Outcome: Incidence of lymph node metastasis
Study design: RCT or non-RCT

Q3. Is the risk of lymph node metastasis higher in the submucosal invasive colorectal cancer with lymphovascular invasion than in the submucosal invasive colorectal cancer without lymphovascular invasion?

Patient: Patients who were diagnosed with submucosal colorectal cancer

Patient: Patients who were diagnosed with submucosal colorectal cancer with lymphovascular invasion

Comparator: Patients who were diagnosed with submucosal colorectal cancer without lymphovascular invasion

Outcome: Incidence of lymph node metastasis

Study design: RCT or non-RCT

Q4. Is the risk of lymph node metastasis higher in the submucosal invasive colorectal cancer with tumor budding than in the submucosal invasive colorectal cancer without tumor budding?

Patient: Patients who were diagnosed with submucosal colorectal cancer

Patient: Patients who were diagnosed with submucosal colorectal cancer with tumor budding

Comparator: Patients who were diagnosed with submucosal colorectal cancer without tumor budding

Outcome: Incidence of lymph node metastasis

Study design: RCT or non-RCT

Q5. Is the risk of lymph node metastasis higher in the poorly differentiated early colorectal cancer than in the well or moderately differentiated early colorectal cancer?

Patient: Patients who were diagnosed with early colorectal cancer

Intervention: Patients who were diagnosed with poorly differentiated early colorectal cancer

Comparator: Patients who were diagnosed with well or moderately differentiated early colorectal cancer

Outcome: Incidence of lymph node metastasis

Study design: RCT or non-RCT

Statement C2: Endoscopic resection of submucosal colorectal cancer with a high risk of lymph node metastasis has a higher recurrence rate than surgical resection. Therefore, we recommend additional surgery if histological signs after endoscopic resection suggest a high risk of lymph node metastasis. (Grade of recommendation: strong, Level of evidence: high)

Q1. Are the recurrence and survival rates different between the endoscopic resection and the surgical resection for the submucosal invasive colorectal cancer with low risk of lymph node metastasis?

Patient: Patients who were diagnosed with submucosal colorectal cancer with low risk of lymph node metastasis

Intervention: Endoscopic resection

Comparator: Surgery

Outcome: Recurrence and/or survival rates

Study design: RCT or non-RCT

Q2. Are the recurrence and survival rates different between the endoscopic resection and the surgical resection for the submucosal invasive colorectal cancer with high risk of lymph node metastasis?

Patient: Patients who were diagnosed with submucosal colorectal cancer with high risk of lymph node metastasis

Intervention: Endoscopic resection

Comparator: Surgery

Outcome: Recurrence and/or survival rates

Study design: RCT or non-RCT

Statement C3: We recommend endoscopic assessment of pit patterns and vascular patterns to estimate the depth of submucosal invasion before endoscopic resection of early colorectal cancer. (Grade of recommendation: strong, Level of evidence: high)

Q1. For the diagnosis of suspected/established early colorectal cancer, is narrow band imaging useful to differentiate mucosal/superficial submucosal cancer from deep submucosal cancer compared with white light endoscopy?

Patient: Patients who have suspected or established early colorectal cancer
Intervention: Narrow band imaging
Comparator: White light endoscopy
Outcome: Differentiation of mucosal/superficial submucosal cancer from deep submucosal cancer (diagnostic accuracy)
Study design: RCT or non-RCT

Q2. For the diagnosis of suspected/established early colorectal cancer, is chromoendoscopy useful to differentiate mucosal/superficial submucosal cancer from deep submucosal cancer compared with white light endoscopy?

Patient: Patients who have suspected or established early colorectal cancer
Intervention: Chromoendoscopy
Comparator: White light endoscopy
Outcome: Differentiation of mucosal/superficial submucosal cancer from deep submucosal cancer (diagnostic accuracy)
Study design: RCT or non-RCT

Q3. For the diagnosis of suspected/established early colorectal cancer, is magnifying endoscopy useful to differentiate mucosal/superficial submucosal cancer from deep submucosal cancer compared with conventional endoscopy?

Patient: Patients who have suspected or established early colorectal cancer
Intervention: Magnifying endoscopy
Comparator: Conventional (non-magnifying) endoscopy
Outcome: Differentiation of mucosal/superficial submucosal cancer from deep submucosal cancer (diagnostic accuracy)
Study design: RCT or non-RCT


Statement C4. En bloc and histologically complete resection should be achieved for endoscopic treatment of a suspected or established early colorectal cancer. We recommend endoscopic submucosal dissection for the treatment of endoscopically resectable early colorectal cancer which cannot be resected en bloc using endoscopic mucosal resection technique. (Grade of recommendation: strong, Level of evidence: moderate)

Q1. Does endoscopic submucosal dissection provide higher en bloc resection rate for suspected or established early colorectal cancer than endoscopic mucosal resection or other endoscopic resection techniques?


Patient: Patients who have suspected or established early colorectal cancer
Intervention: Endoscopic submucosal dissection
Comparator: Endoscopic mucosal resection, endoscopic resection techniques other than endoscopic submucosal dissection
Outcome: En bloc resection rate
Study design: RCT or non-RCT


Supplementary Material 2. Search Flowcharts


1. Superficial Esophageal Squamous Cell Carcinoma





2. Early Gastric Cancer
































3. Early Colorectal Cancer

